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aSchool of Engineering and Physical Sciences, Heriot Watt University, Edinburgh, UK; bSchool of Medical Sciences, Bangor University, Bangor,
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ABSTRACT
The liver is one of the most important multi-functional organs in the human body. Amongst
various crucial functions, it is the main detoxification center and predominantly implicated in the
clearance of xenobiotics potentially including particulates that reach this organ. It is now well
established that a significant quantity of injected, ingested or inhaled nanomaterials (NMs)
translocate from primary exposure sites and accumulate in liver. This review aimed to summarize
and discuss the progress made in the field of hepatic nanotoxicology, and crucially highlight
knowledge gaps that still exist.
Key considerations include
● In vivo studies clearly demonstrate that low-solubility NMs predominantly
accumulate in the liver macrophages the Kupffer cells (KC), rather than
hepatocytes.
● KCs lining the liver sinusoids are the first cell type that comes in contact with
NMs in vivo. Further, these macrophages govern overall inflammatory
responses in a healthy liver. Therefore, interaction with of NM with KCs
in vitro appears to be very important.
● Many acute in vivo studies demonstrated signs of toxicity induced by
a variety of NMs. However, acute studies may not be that meaningful due
to liver’s unique and unparalleled ability to regenerate. In almost all investi-
gations where a recovery period was included, the healthy liver was able to
recover from NM challenge. This organ’s ability to regenerate cannot be
reproduced in vitro. However, recommendations and evidence is offered for
the design of more physiologically relevant in vitro models.
● Models of hepatic disease enhance the NM-induced hepatotoxicity.
The review offers a number of important suggestions for the future of hepatic nanotoxicology
study design. This is of great significance as its findings are highly relevant due to the develop-
ment of more advanced in vitro, and in silico models aiming to improve physiologically relevant
toxicological testing strategies and bridging the gap between in vitro and in vivo experimentation.
KEYWORDS
Liver; nanomaterials; Kupffer
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Introduction
The rapid expansion and exploitation of engi-
neered nanomaterials (NMs) (“manufactured
material in an unbound state or as an aggregate
or as an agglomerate and where, for 50% or more
of the particles in the number size distribution,
one or more external dimensions is in the size
range 1–100 nm” EU commission recommenda-
tion 2011) has led to considerable interest in the
fields of nanotechnology and nanomedicine
(Kermanizadeh et al. 2018; Vance et al. 2015).
However, the unique chemical and physical char-
acteristics which make NMs desirable might also
contribute to their potential adverse health effects.
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With the inevitable rise of occupational and gen-
eral public exposure due to increasing production
and utilization of NMs, there is an urgent need to
consider the possibility of potential detrimental
health consequences of exposure to these materials
(Johnston et al. 2012; Kermanizadeh et al. 2015,
2016; Laux et al. 2018). The small size of NMs
results in high surface area to volume ratio,
which might offer enhanced biological activity
per given mass compared to larger-size counter-
parts (Johnston et al. 2012). Any comprehensive
testing strategy for particulates needs to incorpo-
rate information on parameters such as surface
area, surface chemistry, size distribution and sur-
face charge (Oberdorster et al. 2005). In reality, it
is possible that NMs might differ in the severity of
toxicity and the mechanism by which adverse
effects are exerted.
The lungs and the gastrointestinal tract (GIT) are
in continual contact with the external environment
and are primary and principal exposure sites for
NMs (Laux et al. 2018; Sadauskas et al. 2009). It is
well-known that a proportion of NMs translocate to
a range of secondary organs with the liver being one
of the most important in terms of the quantities of
NM accumulation (Balasubramanian et al. 2010;
Kermanizadeh et al. 2015; Lee et al. 2013; Lipka
et al. 2010). In addition, with constant advances in
nanomedicines, these may result in direct entry of
NMs into the bloodstream. The presence of NMs in
blood might consequently enable in materials reach-
ing the liver rapidly and in large concentrations
(Balasubramanian et al. 2010; Kermanizadeh et al.
2015). Therefore, it might be argued that for parti-
culates in the blood, the liver stands in the forefront
of a NM challenge.
The liver is the body’s main detoxification cen-
ter, removing waste products (i.e. bilirubin) or
foreign substances (Kmiec 2001; Nguyen-Lefebvre
and Horuzsko 2015). The organ consists of highly
organized parenchyma which is represented by
hepatocytes and numerous non-parenchymal cell
populations including resident macrophages such
as Kupffer cells (KCs) that are involved in xeno-
biotic elimination (Godoy et al. 2014;
Kermanizadeh et al. 2019b, 2014a; Tiegs and
Lohse 2010). In particular and of great significance
in particle hepatotoxicity is the fact that KCs and
sinusoidal endothelial cells line the liver sinusoids.
This organ architecture and environment means
that these cells have continuous contact with gut-
originated antigens as well as any material, which
reaches the organ from the blood. In liver blood
flow occurs via the sinusoids which are lined with
endothelial cells and KCs. Due to the locality of
the KCs in the wall of sinusoids, this sub-
population might act as a barrier to the non-
soluble NMs, preventing them from reaching the
hepatocytes. In addition, activated KCs are one of
the most important hepatic cell populations in
modulation and governance of the organs immune
response both in health and disease states
(Bottcher, Knolle, and Stabenow 2011;
Kermanizadeh et al. 2014a; Tiegs and Lohse
2010; Zhu et al. 2017).
This review is a follow-up to our 2013 review
published in British Journal of Pharmacology
(Kermanizadeh et al. 2014b). The aim of this
investigation was to highlight the progress made
in the research in the area of NM-induced hepatic
toxicity since 2013 and the knowledge gaps that
still exist. The main body of the manuscript sum-
marizes a wide range of relevant studies carried
out between 2013 and 2019, which focused on
hepatic NM-induced adverse effects, bio-
accumulation in vivo, or toxicity using in vitro or
ex vivo models. Each study was intentionally seg-
regated and abridged in detail to enable the reader
real context and providing important and relevant
experimental detail. The search criteria included
a combination of the following terms: “nanoparti-
cles,” “nanomaterials,” “hepatic,” “liver,” “liver tis-
sue,” “toxicity,” “cytotoxicity,” “adverse effects,”
“bio-distribution,” “distribution,” “translocation,”
“hepatocytes,” “HepG2” “HepaRG,” “C3A,”
“Chang cells,” “gastrointestinal tract,” “Kupffer
cells,” “primary liver cells,” “primary hepatic
cells,” “oral exposure,” “intravenous exposure,”
“dermal exposure” and “inhalation.” The last lit-
erature search was conducted on 16-12-2019.
Due to the inevitable limitations and exclusion-
ary nature of any literature search; studies that did
not include the search terms in the title or did not
provide adequate information in the abstract
might have been unintentionally omitted.
However, importantly all relevant negative data
from the investigations in which hepatic toxicity
or bioaccumulation was investigated but not
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observed are included (and highlighted in Table
1). The focus of the review is primarily based upon
human and rodent models as these have been the
predominant investigated experimental models in
the literature, although a few studies in other
models do such as aquatic, invertebrate or avian
species exist (Al-Badri et al. 2019; Campbell et al.
2018; Gao et al. 2018; Gagne et al. 2013;
Hernandez-Moreno et al. 2019; Lekamge et al.
2019; Lecave et al. 2018; Ramachandran et al.
2018). Further, any study that did not provide
adequate material characterization data were
excluded. This review only focused on engineered
NMs and not nanomedicines (nanocarriers or
solid drug NMs) or naturally occurring com-
pounds. Finally, from a toxicological perspective,
it is important to state that investigations which
utilized high non-physiological concentrations/
doses are included in this review as these are
a prominent and representative proportion of the
current NM-induced liver toxicology research
landscape. This issue will be highlighted on an
individual basis. The main body of text only
includes a selection of representative publications
over the last 5 years. However, Table 1 contains all
studies that were identified as suitable for this
literature review, with the overall conclusions and
recommendations based upon all the literature
summarized in Table 1.
The review is structured into in vivo (further
segregated by route of exposure and solubility of
the NM being discussed) and in vitro/ex vivo sec-
tions. The final section concludes with
a summation of the progress made in the field
since 2013, along with our thoughts on the areas
of research, which are still lacking and some
recommendations for future and progression of
hepatic nanotoxicology.
Engineered NMs and the liver – in vivo
studies
Intravenous (iv)route of exposure
Intravenous (iv) exposure of male Sprague-Dawley
rats weighing approximately 150 g to a 20 nm Ag
NM at a single dose of 50 mg/kg for 24 hr resulted
in significantly increased activities of serum aspar-
tate transaminase (AST) by 54%, alanine
transaminase (ALT) by 76%, acid phosphatase
(ACP) by 82% and alkaline phosphatase (ALP)
by 85%, compared to control rats (Kumar and
Abraham 2016). Further, the Ag NM-treated rats
exhibited decreased activities of catalase and
superoxide dismutase (SOD) and higher concen-
trations of thiobarbituric acid reactive substances
(TBARS) compared to controls. These serum bio-
markers are traditionally utilized as indicators of
liver damage. Finally, Ag treatment resulted in
eosinophilic necrosis of hepatocytes, dilated cen-
tral vein and focal inflammatory cell infiltration in
the examined liver sections (Kumar and Abraham
2016).
In another study, the role of KC in the immu-
notoxicological hepatic response to Ag NMs
(approximately 50 nm) was investigated in 10-
week-old female C57BL/6 mice following a single
IV exposure (Kermanizadeh et al. 2014a). In these
experiments, the KC population was reduced via iv
administration of clodronate liposomes for 48 hr
prior to animals receiving NMs (24 µg per animal)
for periods of 24, 48 or 72 hr. In the livers in
which the KC population was specifically
destroyed the levels of inflammatory cytokines
were significantly decreased compared to controls.
Kermanizadeh et al. (2014a) also noted high levels
of interleukin (IL) 10 released from Ag treated
hepatic tissue of normal mice in comparison to
KC depleted livers, suggesting involvement of the
KCs in orchestrating an anti-inflammatory
response to a low dose NM challenge in
a healthy liver. It is noteworthy that IL10 is
a potent anti-inflammatory cytokine involved in
the maintenance of immune tolerance in
a healthy organ.
The adverse hepatic effects of iv administration
of Ag NM (approximately 30 nm) were investi-
gated in models of alcoholic hepatic disease
in vitro and in vivo. In this set of trials, 8-week-
old female C57BL/6 mice were divided into two
groups with one receiving an all liquid diet for
25 days while the other group were fed an all
liquid diet supplemented with 5% ethanol. The
animals were injected with a single dose of either
25 or 100 µg of the NMs for 24 or 168 hr.
Kermanizadeh et al. (2017a) demonstrated that
NM-induced adverse hepatic health effects were
significantly enhanced in alcohol-fed mice in
JOURNAL OF TOXICOLOGY & ENVIRONMENTAL HEALTH, PART B 139
Ta
bl
e
1.
Th
e
su
m
m
ar
y
of
th
e
ac
cu
m
ul
at
io
n
an
d
ad
ve
rs
e
ef
fe
ct
s
of
na
no
m
at
er
ia
ls
on
th
e
liv
er
fr
om
st
ud
ie
s
30
13
–2
01
9
fo
llo
w
in
g
ex
po
su
re
vi
a
IV
,o
ra
l,
in
ha
la
tio
n,
IT
,i
nt
ra
na
sa
l,
IP
an
d
de
rm
al
ro
ut
es
.
N
M
Si
ze
Ro
ut
e
of
N
M
ex
po
su
re
Sp
ec
ie
s
D
os
e
N
um
be
r
of
ex
po
su
re
s
Ex
po
su
re
du
ra
tio
n
H
ep
at
ic
ef
fe
ct
s
H
is
to
pa
th
ol
og
y
Re
co
ve
ry
pe
rio
d
in
cl
ud
ed
/
H
ep
at
ic
re
co
ve
ry
ob
se
rv
ed
Re
fe
re
nc
e
Ag
20
nm
IV
Sp
ra
gu
e-
D
aw
le
y
ra
ts
50
m
g/
kg
1
24
hr
In
cr
ea
se
d
AS
T,
AL
T,
AC
P,
AL
P,
TB
AR
S
an
d
de
cr
ea
se
d
CA
T,
SO
D
N
ec
ro
si
s
of
he
pa
to
cy
te
s,
di
la
te
d
ce
nt
ra
lv
ei
n
an
d
fo
ca
l
in
fla
m
m
at
or
y
ce
ll
in
fil
tr
at
io
n
N
o
Ku
m
ar
an
d
Ab
ra
ha
m
20
16
PV
P-
co
at
ed
Ag
PV
P-
co
at
ed
Ag
si
lic
on
-c
oa
te
d
Ag
5
nm
50
nm
45
nm
IV
B6
C3
F1
m
ic
e
25
m
g/
kg
1
or
3
24
hr
Al
lN
M
s
in
du
ce
d
ox
id
at
iv
e
D
N
A
da
m
ag
e
N
ot
an
al
yz
ed
N
o
Li
et
al
.2
01
4
Ci
tr
at
e
or
PV
P
co
at
ed
Ag
10
nm
40
nm
10
0
nm
IV
CD
-1
m
ic
e
10
m
g/
kg
1
24
hr
N
ot
an
al
yz
ed
Le
si
on
s
in
th
e
liv
er
pr
es
en
t
an
d
N
M
si
ze
-
de
pe
nd
en
t
N
o
Re
co
rd
at
ie
t
al
.
20
15
Ag
50
nm
IV
C5
7B
L/
6
m
ic
e
24
µg
/a
ni
m
al
1
24
,4
8
or
72
hr
KC
m
ed
ia
te
d
an
ti-
in
fla
m
m
at
or
y
re
sp
on
se
N
ot
an
al
yz
ed
N
o
Ke
rm
an
iz
ad
eh
et
al
.2
01
4a
Ag
30
nm
IV
H
ea
lth
y
an
d
al
co
ho
l
fe
d
C5
7B
L/
6
m
ic
e
25
or
10
0
µg
/
an
im
al
1
24
or
16
8
hr
In
fla
m
m
at
or
y
re
sp
on
se
,
ch
an
ge
s
in
bl
oo
d
bi
oc
he
m
is
tr
y,
ac
ut
e
ph
as
e
re
sp
on
se
(a
ll
ag
gr
av
at
ed
in
th
e
di
se
as
ed
an
im
al
s)
Ch
an
ge
s
in
in
tr
ah
ep
at
ic
ar
ch
ite
ct
ur
e,
gr
an
ul
om
a
fo
rm
at
io
n,
he
pa
to
cy
te
ne
cr
os
is
,
pa
re
nc
hy
m
at
ou
s
de
ge
ne
ra
tio
n
an
d
th
e
de
st
ru
ct
io
n
of
th
e
liv
er
pl
at
es
Ye
s/
Ye
s
Ke
rm
an
iz
ad
eh
et
al
.2
01
7a
Au Ag or
m
ix
10
nm
10
nm
IV
Sp
ra
gu
e-
D
aw
le
y
ra
ts
10
or
10
0
µg
/
kg
/d
ay
1
U
p
to
4
w
ee
ks
N
M
ac
cu
m
ul
at
io
n
on
ly
/n
o
ad
ve
rs
e
ef
fe
ct
s
N
ot
an
al
yz
ed
N
o
Le
e
et
al
.2
01
8
Su
pe
rp
ar
am
ag
ne
tic
zi
nc
-c
ob
al
t
fe
rr
ite
8
nm
IV
N
ew
Ze
al
an
d
ra
bb
its
20
m
g/
an
im
al
1
4
hr
N
ot
an
al
yz
ed
G
ra
nu
lo
m
a
fo
rm
at
io
n
an
d
m
ul
tip
le
co
ng
es
tio
ns
N
o
H
an
in
ie
t
al
.2
01
6
Zn
O
Q
D
PE
G
yl
at
ed
-Z
nO
Q
D
5
nm
95
nm
IV
Ku
nm
in
g
m
ic
e
5
m
g/
kg
7
da
ily
do
se
s
1–
7
da
ys
N
o
ch
an
ge
s
in
AL
T
an
d
AS
T
ac
tiv
ity
N
ot
an
al
yz
ed
N
o
Ya
ng
et
al
.2
01
4
Zn
-la
be
le
d
Cd
Se
/
Cd
S/
Zn
S-
Q
D
11
nm
IV
FV
B/
N
m
ic
e
50
–1
00
pm
ol
/
an
im
al
1
2
hr
N
ot
an
al
yz
ed
Ac
cu
m
ul
at
io
n
in
KC
s
bu
t
no
t
he
pa
to
cy
te
s
N
o
Ba
rg
he
er
et
al
.
20
15
M
EA
an
d
M
PA
co
at
ed
Ag
2S
e
Q
D
5
nm
5
nm
IV
CD
-1
m
ic
e
8
µm
ol
/k
g
1
2
m
in
–
28
da
ys
N
ot
an
al
yz
ed
M
ild
ed
em
a
in
th
e
liv
er
in
th
e
Q
D
s-
M
EA
gr
ou
p
Ye
s/
N
o
Ta
ng
et
al
.2
01
7
O
le
ic
ac
id
PE
G
yl
at
ed
Cd
Se
S/
Zn
S
Q
D
60
nm
10
0
nm
IV
W
is
ta
r
ra
ts
14
µg
/a
ni
m
al
1
12
hr
Q
D
s
pr
ed
om
in
at
el
y
ta
ke
n
up
by
KC
s
N
ot
an
al
yz
ed
N
o
Ts
oi
et
al
.2
01
6
(C
on
tin
ue
d
)
140 A. KERMANIZADEH ET AL.
Ta
bl
e
1.
(C
on
tin
ue
d)
.
N
M
Si
ze
Ro
ut
e
of
N
M
ex
po
su
re
Sp
ec
ie
s
D
os
e
N
um
be
r
of
ex
po
su
re
s
Ex
po
su
re
du
ra
tio
n
H
ep
at
ic
ef
fe
ct
s
H
is
to
pa
th
ol
og
y
Re
co
ve
ry
pe
rio
d
in
cl
ud
ed
/
H
ep
at
ic
re
co
ve
ry
ob
se
rv
ed
Re
fe
re
nc
e
Cd
Te
-Q
D
~
15
nm
IV
BA
LB
/c
m
ic
e
0.
4,
2,
5,
6,
7
or
10
m
g/
kg
1
24
hr
In
cr
ea
se
s
in
AS
T,
AL
T,
to
ta
lb
ili
ru
bi
n
an
d
SA
A
le
ve
ls
,r
ed
uc
ed
al
bu
m
in
le
ve
ls
at
th
e
hi
gh
es
t
do
se
s
6
m
g/
kg
bw
an
d
hi
gh
er
in
du
ce
d
liv
er
he
m
or
rh
ag
e
ob
se
rv
ed
in
th
e
pe
rip
or
ta
la
re
as
of
th
e
he
pa
tic
lo
bu
le
s
ac
co
m
pa
ni
ed
by
ap
op
to
tic
an
d
ne
cr
ot
ic
liv
er
ce
lls
in
th
os
e
ar
ea
s
N
o
N
gu
ye
n
et
al
.2
01
9
Ca
rb
ox
yl
co
at
ed
Cd
Se
/Z
nS
Q
D
20
nm
IV
Pr
eg
na
nt
an
d
of
fs
pr
in
g
Sp
ra
gu
e-
D
aw
le
y
ra
ts
1
or
5
nm
ol
1
U
p
to
18
0
da
ys
In
cr
ea
se
d
AL
T,
AS
T,
bi
lir
ub
in
an
d
ga
m
m
a
gl
ut
am
yl
tr
an
sa
m
in
as
e
in
th
e
m
ot
he
rs
H
ep
at
ic
ce
llu
la
r
ap
op
to
si
s,
ne
cr
os
is
,
cy
to
ly
si
s,
lo
ss
of
he
pa
tic
lo
bu
le
s
in
th
e
liv
er
s
of
ex
po
se
d
an
im
al
s
at
da
y
1
po
st
ex
po
su
re
Ye
s/
Ye
s
Ya
ng
et
al
.2
01
8a
Si
O
2
~
15
0
nm
IV
Sp
ra
gu
e-
D
aw
le
y
ra
ts
50
m
g/
kg
1
48
hr
In
cr
ea
se
d
AS
T,
to
ta
lb
ile
ac
id
,c
ho
le
st
er
ol
,a
nd
lo
w
-
de
ns
ity
lip
op
ro
te
in
le
ve
ls
In
cr
ea
se
in
th
e
nu
m
be
r
of
th
e
KC
s
N
o
Ch
en
et
al
.2
01
7
Si
O
2
50
nm
IV
At
hy
m
ic
nu
de
m
ic
e
20
m
g/
kg
1
U
p
to
7
da
ys
In
cr
ea
se
in
AL
T
an
d
ca
ta
la
se
ac
tiv
ity
N
ot
an
al
yz
ed
Ye
s/
Ye
s
Ba
at
ie
t
al
.2
01
6
Si
O
2
Fe
-S
iO
2
ho
llo
w
na
no
sh
el
ls
50
0
nm
50
0
nm
IV
Sw
is
s
w
hi
te
m
ic
e
2–
20
m
g/
kg
1
24
hr
N
o
ch
an
ge
s
in
se
ru
m
bi
oc
he
m
is
tr
y
O
nl
y
m
ild
pa
th
ol
og
y
m
an
ife
st
ed
as
ly
m
ph
oc
yt
ic
in
fil
tr
at
io
n
Ye
s/
Ye
s
M
en
de
z
et
al
.2
01
7
Si
O
2
11
0
nm
IV
W
T
BA
LB
/c
or
N
LR
P3
−
/−
or
Ca
sp
as
e
1−
/−
m
ic
e
25
or
50
m
g/
kg
3
do
se
s
ev
er
y
ot
he
r
da
y
3
w
ee
ks
In
cr
ea
se
d
se
ru
m
AL
T
an
d
AS
T,
in
fla
m
m
at
or
y
re
sp
on
se
N
ot
an
al
yz
ed
Ye
s/
Ye
s
Zh
an
g
et
al
.2
01
8
H
ex
ag
on
al
co
pp
er
su
lfi
de
na
no
pl
at
e
Le
ng
th
of
59
nm
an
d
th
ic
kn
es
s
of
24
nm
IV
IC
R
m
ic
7.
7
to
55
0
m
g/
kg
1
48
hr
N
ot
an
al
yz
ed
N
o
pa
th
ol
og
y
N
o
Fe
ng
et
al
.2
01
5
Po
ly
ac
ry
lic
ac
id
-
co
at
ed
iro
n
ox
id
e
~
10
nm
IV
CD
-1
m
ic
e
8,
20
or
50
m
g/
kg
1
24
hr
N
ot
an
al
yz
ed
N
ec
ro
tic
he
pa
to
cy
te
s,
N
M
on
ly
vi
si
bl
e
in
KC
s
N
o
Ro
dr
ig
ue
s
et
al
.
20
17
(C
on
tin
ue
d
)
JOURNAL OF TOXICOLOGY & ENVIRONMENTAL HEALTH, PART B 141
Ta
bl
e
1.
(C
on
tin
ue
d)
.
N
M
Si
ze
Ro
ut
e
of
N
M
ex
po
su
re
Sp
ec
ie
s
D
os
e
N
um
be
r
of
ex
po
su
re
s
Ex
po
su
re
du
ra
tio
n
H
ep
at
ic
ef
fe
ct
s
H
is
to
pa
th
ol
og
y
Re
co
ve
ry
pe
rio
d
in
cl
ud
ed
/
H
ep
at
ic
re
co
ve
ry
ob
se
rv
ed
Re
fe
re
nc
e
Iro
n
ox
id
e
m
ag
ne
tic
N
M
s
co
at
ed
w
ith
PE
G
,B
SA
an
d
CO
O
H
al
l~
50
nm
IV
Sp
ra
gu
e-
D
aw
le
y
ra
t
50
m
g/
kg
2
U
p
to
24
da
ys
D
ay
1
po
st
in
je
ct
io
n
AL
T,
AS
T,
to
ta
lp
ro
te
in
in
cr
ea
se
d
by
PE
G
an
d
CO
O
H
N
M
s;
AL
T,
AS
T,
to
ta
lp
ro
te
in
in
cr
ea
se
d
by
BS
A
an
d
CO
O
H
N
M
s
N
o
si
gn
ifi
ca
nt
hi
st
ol
og
ic
al
al
te
rn
at
io
ns
w
er
e
de
te
ct
ed
Ye
s/
Ye
s
Ya
ng
et
al
.2
01
8b
Au
/F
eO
4
N
M
s
co
at
ed
w
ith
am
ph
ip
hi
lic
po
ly
m
er
or
PE
G
~
10
0
nm
IV
C5
7/
BL
6
m
ic
e
56
µg
iro
n
1
U
p
to
36
5
da
ys
N
M
s
de
te
ct
ab
le
in
KC
s
fo
r
up
to
1
ye
ar
N
o
pa
th
ol
og
y
Ye
s/
N
A
Ko
lo
sn
ja
j-T
ab
i
et
al
.2
01
5
Au
na
no
ro
d
22
0
nm
IV
CD
-1
m
ic
e
5
m
g/
kg
1
U
p
to
28
da
ys
In
cr
ea
se
d
ϒ
-
gl
ut
am
yl
tr
an
sf
er
as
e,
bi
lir
ub
in
an
d
to
ta
lb
ile
de
cr
ea
se
d
SO
D
,G
SH
an
d
G
SH
-P
x
N
o
hi
st
ol
og
ic
al
al
te
rn
at
io
ns
w
er
e
de
te
ct
ed
–
ex
cl
us
iv
el
y
in
th
e
KC
s
Ye
s/
Ye
s
Ca
ie
t
al
.2
01
6
Au
~
15
nm
IV
BA
LB
/c
m
ic
e
F3
44
ra
ts
10
00
m
g/
kg
1
U
p
to
28
da
ys
N
o
ch
an
ge
s
in
se
ru
m
bi
oc
he
m
is
tr
y
M
ic
ro
-g
ra
nu
lo
m
as
,
N
M
s
pr
ed
om
in
at
el
y
in
KC
Ye
s/
Ye
s
Ba
ha
m
on
de
et
al
.
20
18
Au
pr
is
m
s
10
nm
w
ith
th
re
e
ed
ge
le
ng
th
s
of
~
15
0
nm
IV
Sw
is
s
m
ic
e
6
µg
/g
1
72
hr
or
4
m
on
th
s
N
o
se
ru
m
bi
oc
he
m
is
tr
y
al
te
ra
tio
ns
En
la
rg
ed
va
cu
ol
es
,
N
M
ac
cu
m
ul
at
io
n
in
KC
s
Ye
s/
N
A
Pé
re
z-
H
er
ná
nd
ez
et
al
.2
01
7
Au
10
nm
50
nm
ro
ds
60
×
30
nm
st
ar
s
55
nm
IV
CD
-1
m
ic
e
1.
54
×
10
10
N
M
s
1
U
p
to
12
0
hr
N
ot
an
al
yz
ed
N
o
pa
th
ol
og
y
N
o
Ta
la
m
in
ie
t
al
.
20
17
Ch
ito
sa
n-
ca
pp
ed
st
ar
Au
Au
na
no
ro
d
~
11
0
nm
18
nm
w
id
th
,
58
nm
le
ng
th
IV
BA
LB
/c
m
ic
e
2
m
g/
kg
1
2
m
g/
kg
To
xi
ci
ty
no
t
an
al
yz
ed
/N
M
ac
cu
m
ul
at
io
n
in
th
e
liv
er
N
ot
an
al
yz
ed
N
o
W
an
g
et
al
.2
01
5
PE
G
yl
at
ed
Au
~
6
nm
25
nm
40
nm
60
nm
IV
Ku
nm
in
g
m
ic
e
3
m
g/
kg
1
U
p
to
90
da
ys
N
o
se
ru
m
bi
oc
he
m
is
tr
y
al
te
ra
tio
ns
N
ot
an
al
yz
ed
Ye
s/
N
A
Li
et
al
.2
01
8b
D
ex
tr
an
co
at
ed
Au
20
nm
IV
At
hy
m
ic
nu
de
m
ic
e
1
m
g/
kg
1
24
hr
,7
or
14
da
ys
N
o
se
ru
m
bi
oc
he
m
is
tr
y
al
te
ra
tio
ns
N
o
pa
th
ol
og
y
Ye
s/
N
A
Ba
ill
y
et
al
.2
01
9
Ti
O
2
~
15
0
nm
IV
C5
7B
L/
6
J
gp
t
m
ic
e
2,
10
an
d
50
m
g/
kg
4
(o
nc
e
a
w
ee
k)
4
w
ee
ks
N
o
ge
no
to
xi
c
ef
fe
ct
ob
se
rv
ed
N
M
ac
cu
m
ul
at
io
n
in
KC
s
N
o
Su
zu
ki
et
al
.2
01
6
Ti
O
2
~
20
nm
IV
C5
7B
L/
6
m
ic
e
(w
ith
pU
R2
88
pl
as
m
id
)
10
or
15
m
g/
kg
/d
ay
2
28
da
ys
N
o
ge
no
to
xi
c
ef
fe
ct
ob
se
rv
ed
N
ot
an
al
yz
ed
Ye
s/
N
A
Lo
ur
o
et
al
.2
01
4
(C
on
tin
ue
d
)
142 A. KERMANIZADEH ET AL.
Ta
bl
e
1.
(C
on
tin
ue
d)
.
N
M
Si
ze
Ro
ut
e
of
N
M
ex
po
su
re
Sp
ec
ie
s
D
os
e
N
um
be
r
of
ex
po
su
re
s
Ex
po
su
re
du
ra
tio
n
H
ep
at
ic
ef
fe
ct
s
H
is
to
pa
th
ol
og
y
Re
co
ve
ry
pe
rio
d
in
cl
ud
ed
/
H
ep
at
ic
re
co
ve
ry
ob
se
rv
ed
Re
fe
re
nc
e
N
i
~
50
nm
IV
Sp
ra
gu
e
D
aw
le
y
ra
ts
1,
10
or
20
m
g/
kg
1
14
da
ys
In
cr
ea
se
in
bi
om
ar
ke
rs
of
liv
er
da
m
ag
e
M
ild
da
m
ag
e
–
di
st
or
te
d
ar
ch
ite
ct
ur
e
of
th
e
si
nu
so
id
s
Ye
s/
N
o
M
ag
ay
e
et
al
.2
01
4
PE
G
yl
at
ed
pl
at
in
um
2–
4
nm
IV
BA
LB
/c
m
ic
e
5,
10
,1
5
an
d
20
m
g/
kg
1
24
hr
N
o
se
ru
m
bi
oc
he
m
is
tr
y
al
te
ra
tio
ns
N
o
pa
th
ol
og
y
N
o
Br
ow
n
et
al
.2
01
8
Al
um
in
a
na
no
tu
be
~
70
0
nm
lo
ng
an
d
90
nm
in
di
am
et
er
)
IV
BA
LB
/c
m
ic
e
20
,5
0,
10
0
m
/
kg
1
U
p
to
28
da
ys
In
fil
tr
at
io
n
of
in
fla
m
m
at
or
y
ce
lls
in
th
e
liv
er
s
N
o
pa
th
ol
og
y
Ye
s/
Ye
s
W
an
g
et
al
.2
01
7
Al
O
90
nm
11
0
nm
IV
IC
R
m
ic
e
1.
5
or
5
m
g/
kg
1
U
p
to
14
da
ys
N
o
ch
an
ge
s
in
se
ru
m
bi
oc
he
m
is
tr
y
In
fla
m
m
at
or
y
ce
ll
in
fil
tr
at
io
n
Ye
s/
N
A
Pa
rk
et
al
.2
01
6a
Zr
O
2
15
0
nm
IV
IC
R
m
ic
e
30
0,
40
0,
50
0
an
d
60
0
m
g/
kg
1
In
cr
ea
se
d
se
ru
m
AL
T
le
ve
ls
at
50
0
m
g/
kg
N
o
pa
th
ol
og
y
N
o
Ya
ng
et
al
.2
01
9
Re
du
ce
d
gr
ap
he
ne
ox
id
e
~
35
0
nm
IV
W
is
ta
r
ra
ts
7
m
g/
kg
1
1,
3
hr
or
7
da
ys
N
o
se
ru
m
bi
oc
he
m
is
tr
y
al
te
ra
tio
ns
w
er
e
de
te
ct
ed
N
o
pa
th
ol
og
y
N
o
M
en
do
nç
a
et
al
.
20
16
G
ra
ph
en
e
ox
id
e
fu
nc
tio
na
liz
ed
w
ith
po
ly
so
di
um
4-
st
yr
en
es
ul
fo
na
te
~
70
0
nm
IV
BA
LB
/c
m
ic
e
U
p
to
16
m
g/
kg
1
U
p
18
0
da
ys
In
cr
ea
se
in
AL
T
an
d
AS
T
ac
tiv
ity
Bl
ac
k
le
si
on
s
m
os
tly
in
th
e
KC
s
Ye
s/
Ye
s
W
en
et
al
.
20
15
N
an
oc
la
y
M
ix
ed
m
at
er
ia
ls
iz
e
of
~
60
or
~
65
0
nm
IV
BA
LB
/c
m
al
e
m
ic
e
U
p
to
20
m
g/
kg
1
24
hr
In
cr
ea
se
d
AL
T
an
d
AS
T
ac
tiv
ity
La
rg
e
re
gi
on
s
of
ce
llu
la
r
ne
cr
os
is
N
o
Is
od
a
et
al
.2
01
7
M
es
op
or
ou
s
Si
co
at
ed
bi
oa
ct
iv
e
gl
as
s
N
M
s
~
25
0
nm
IV
IC
R
m
ic
e
20
,1
00
an
d
18
0
m
g/
kg
/d
ay
14
14
da
ys
In
cr
ea
se
d
AL
P
at
th
e
hi
gh
es
t
do
se
Ly
m
ph
oc
yt
ic
in
fil
tr
at
io
n
an
d
gr
an
ul
om
a
fo
rm
at
io
n
N
o
M
ao
et
al
.2
01
6
Si
O
2
20
0
nm
IV
C5
7B
L/
6
m
ic
e
10
0
m
g/
kg
1
24
hr
In
cr
ea
se
d
LC
3-
II
in
he
pa
to
cy
te
s
N
ot
an
al
yz
ed
N
o
Zh
an
g
et
al
.2
01
7
La
nt
ha
ni
de
-b
as
ed
up
co
nv
er
si
on
N
M
~
40
nm
IV
W
T
an
d
KC
de
pl
et
ed
C5
7B
L/
6
m
ic
e
15
0
m
g/
kg
1
24
hr
In
cr
ea
se
d
AL
T
an
d
m
os
t
ev
id
en
t
in
KC
de
pl
et
ed
m
ic
e
In
fil
tr
at
io
n
of
in
fla
m
m
at
or
y
ce
lls
an
d
m
os
t
ev
id
en
t
in
KC
de
pl
et
ed
m
ic
e
N
o
Zh
u
et
al
.2
01
7
Ag
st
ab
ili
ze
d
by
PV
P
or
ci
tr
at
e
st
ab
ili
ze
d
20
nm
11
0
nm
O
ra
l
C5
7B
L/
6
m
ic
e
0.
1,
1
or
10
m
g/
kg
/d
ay
3
U
p
to
9
da
ys
N
ot
an
al
yz
ed
N
o
pa
th
ol
og
y
N
o
Be
rg
in
et
al
.2
01
6
(C
on
tin
ue
d
)
JOURNAL OF TOXICOLOGY & ENVIRONMENTAL HEALTH, PART B 143
Ta
bl
e
1.
(C
on
tin
ue
d)
.
N
M
Si
ze
Ro
ut
e
of
N
M
ex
po
su
re
Sp
ec
ie
s
D
os
e
N
um
be
r
of
ex
po
su
re
s
Ex
po
su
re
du
ra
tio
n
H
ep
at
ic
ef
fe
ct
s
H
is
to
pa
th
ol
og
y
Re
co
ve
ry
pe
rio
d
in
cl
ud
ed
/
H
ep
at
ic
re
co
ve
ry
ob
se
rv
ed
Re
fe
re
nc
e
Ag
~
10
nm
O
ra
l
Sp
ra
gu
e-
D
aw
le
y
ra
ts
U
p
to
10
0
m
g/
kg
/d
ay
5
5
da
ys
In
cr
ea
se
d
RO
S,
D
N
A
da
m
ag
e,
AL
T,
AS
T
an
d
AL
P
at
hi
gh
es
t
do
se
s)
H
ep
at
oc
yt
es
di
sr
up
tio
n,
he
pa
to
ce
llu
la
r
va
cu
ol
at
io
n,
an
d
ce
nt
ra
lv
ei
n
in
ju
ry
N
o
Pa
tlo
lla
,H
ac
ke
tt
,
an
d
Tc
ho
un
w
ou
20
15
Ci
tr
at
e-
m
od
ifi
ed
Ag
20
nm
O
ra
l
W
is
ta
r
ra
ts
40
m
g/
kg
1
4
w
ee
ks
Ch
an
ge
s
in
pr
ot
ei
ns
ex
pr
es
si
on
as
so
ci
at
ed
w
ith
ox
id
at
iv
e
st
re
ss
,
in
fla
m
m
at
or
y
re
sp
on
se
,
ox
id
at
io
n
an
d
de
am
in
at
io
n
Ly
m
ph
oc
yt
e
in
fil
tr
at
io
n
an
d
sw
el
lin
g
of
he
pa
to
cy
te
s
Ye
s/
N
A
Xi
e
et
al
.2
01
8
Ag
~
10
nm
O
ra
l
Pr
eg
na
nt
Sp
ra
gu
e-
D
aw
le
y
ra
ts
U
p
to
10
00
m
g/
kg
13
13
da
ys
D
ec
re
as
e
in
ca
ta
la
se
an
d
G
SH
in
m
at
er
na
ll
iv
er
s
at
th
e
hi
gh
er
do
se
s
N
ot
an
al
yz
ed
N
o
Yu
et
al
.2
01
4
Ag M
W
CN
T
~
10
nm
D
ia
m
et
er
20
–3
0
nm
an
d
le
ng
th
5–
50
µm
O
ra
l
Sw
is
s
al
bi
no
m
ic
e
50
or
10
0
m
g/
kg
14
28
da
ys
D
os
e
de
pe
nd
an
t
D
N
A
da
m
ag
e
fo
r
bo
th
N
M
s
N
ot
an
al
yz
ed
N
o
Aw
as
th
ie
t
al
.
20
15
Zn
O
~
30
nm
O
ra
l
Sp
ra
gu
e-
D
aw
le
y
ra
ts
12
5,
25
0
or
50
0
m
g/
kg
90
90
da
ys
D
ec
re
as
e
in
to
ta
ls
er
um
pr
ot
ei
n
an
d
al
bu
m
in
at
th
e
hi
gh
es
t
do
se
N
o
pa
th
ol
og
y
Ye
s/
N
A
Pa
rk
et
al
.2
01
4
Si
lic
a
sh
el
lw
ith
ei
th
er
flu
or
es
ce
nt
Rh
od
am
in
e
6
G
co
re
or
Cd
Se
/C
dS
/Z
nS
Q
D
s
as
th
e
co
re
~
30
nm
O
ra
l
M
ic
e
(s
pe
ci
es
no
t
sp
ec
ifi
ed
)
0.
1
or
0.
67
m
g/
an
im
al
4
4
da
ys
N
M
ac
cu
m
ul
at
io
n
in
th
e
liv
er
N
ot
an
al
yz
ed
N
o
Za
ne
et
al
.2
01
5
Zn
O
50
nm
O
ra
l
IC
R
m
ic
e
U
p
to
10
,0
00
m
g/
kg
14
14
da
ys
In
cr
ea
se
d
se
ru
m
AS
T
an
d
AL
T
ac
tiv
ity
In
fil
tr
at
io
n
of
in
fla
m
m
at
or
y
ce
lls
in
th
e
po
rt
al
re
gi
on
s
of
liv
er
N
o
Ko
ng
et
al
.2
01
8
Zn
O
20
an
d
~
20
0
nm
O
ra
l
IC
R
m
ic
e-
m
od
el
of
IB
D
1
g/
kg
1
24
hr
H
ig
he
r
qu
an
tit
ie
s
of
Zn
O
de
te
ct
ed
in
th
e
di
se
as
ed
an
im
al
s
N
ot
an
al
yz
ed
N
o
D
u
et
al
.2
01
8
(C
on
tin
ue
d
)
144 A. KERMANIZADEH ET AL.
Ta
bl
e
1.
(C
on
tin
ue
d)
.
N
M
Si
ze
Ro
ut
e
of
N
M
ex
po
su
re
Sp
ec
ie
s
D
os
e
N
um
be
r
of
ex
po
su
re
s
Ex
po
su
re
du
ra
tio
n
H
ep
at
ic
ef
fe
ct
s
H
is
to
pa
th
ol
og
y
Re
co
ve
ry
pe
rio
d
in
cl
ud
ed
/
H
ep
at
ic
re
co
ve
ry
ob
se
rv
ed
Re
fe
re
nc
e
Zn
O
N
M
s
an
d
el
em
en
ta
lP
b
~
14
an
d
60
nm
O
ra
l
C5
7B
L/
6
m
ic
e
no
rm
al
or
hi
gh
fa
t
di
et
s
N
M
s
on
ly
–
20
0
m
g/
kg
or N
M
s/
Pb
–
20
0
an
d
15
0
m
g/
kg
da
ily
14
14
da
ys
Re
du
ct
io
n
in
SO
D
an
d
in
cr
ea
se
in
M
D
A
Sp
ot
ty
ce
ll
ne
cr
os
is
an
d
a
m
ild
va
cu
ol
ar
de
ge
ne
ra
tio
n
N
o
Jia
et
al
.2
01
7
Zn
O
na
no
ro
d
~
20
nm
O
ra
l
Sw
is
s
al
bi
no
m
ic
e
U
p
to
6
m
g/
kg
7
7
da
ys
N
ot
an
al
yz
ed
N
o
pa
th
ol
og
y
N
o
Bo
llu
et
al
.2
01
6
Zn
O
Ti
O
2
Al
2O
3
80
–1
00
nm
50
–7
5
nm
40
–5
0
nm
O
ra
l
Sw
is
s
al
bi
no
m
ic
e
50
0
m
g/
kg
/d
ay
21
21
da
ys
In
cr
ea
se
d
RO
S
an
d
de
cr
ea
se
d
SO
D
an
d
ca
ta
la
se
ac
tiv
ity
N
o
hi
st
ol
og
ic
al
al
te
rn
at
io
ns
w
er
e
de
te
ct
ed
,
Ti
O
2
de
te
ct
ab
le
on
ly
in
KC
s
N
o
Sh
riv
as
ta
va
et
al
.
20
14
Si
O
2
~
15
nm
O
ra
l
Ku
n-
M
in
g
m
ic
e
–
he
al
th
y
or
m
et
ab
ol
ic
sy
nd
ro
m
e
m
od
el
10
m
g/
kg
/d
ay
30
30
da
ys
In
cr
ea
se
d
he
pa
tic
D
N
A
da
m
ag
e
in
th
e
m
et
ab
ol
ic
sy
nd
ro
m
e
m
ic
e
po
st
N
M
ad
m
in
is
tr
at
io
n
In
cr
ea
se
d
he
pa
to
cy
te
ba
llo
on
in
g
an
d
in
fil
tr
at
io
n
of
in
fla
m
m
at
or
y
ce
lls
,
co
lla
ge
n
de
po
si
tio
n
in
m
et
ab
ol
ic
sy
nd
ro
m
e
m
ic
e
po
st
N
M
s
ad
m
in
is
tr
at
io
n
N
o
Li
et
al
.2
01
8a
Si
O
2
~
20
nm
O
ra
l
C5
7B
L/
6
tr
an
sg
en
ic
m
ou
se
m
od
el
,e
xp
re
ss
in
g
th
e
hu
m
an
m
ut
at
ed
(A
53
T)
a-
sy
nu
cl
ei
n
pr
ot
ei
n
(T
gH
uA
53
T)
N
M
s
in
dr
in
ki
ng
w
at
er
fo
r
up
to
18
m
on
th
s
-
U
p
to
18
m
on
th
s
N
ot
an
al
yz
ed
M
in
or
in
fla
m
m
at
or
y
ce
ll
in
fil
tr
at
io
n
in
th
e
po
rt
al
an
d
lo
bu
la
r
re
gi
on
s
N
o
Bo
ud
ar
d
et
al
.
20
19
Si
O
2
Ag Fe
2O
3
~
35
nm
~
20
nm
~
12
0
nm
O
ra
l
Sp
ra
gu
e-
D
aw
le
y
ra
ts
10
00
m
g/
kg
91
13
w
ee
ks
Ag
N
M
in
du
ce
d
sl
ig
ht
in
cr
ea
se
in
se
ru
m
AL
P
N
ot
an
al
yz
ed
N
o
Yu
n
et
al
.2
01
5
Zn
2+
do
pe
d
Fe
3O
4
~
10
nm
O
ra
l
M
ic
e
(s
pe
ci
es
un
sp
ec
ifi
ed
)
50
m
g/
kg
/d
ay
30
30
da
ys
In
cr
ea
se
d
LD
H
,A
LT
,A
ST
,
TB
IL
an
d
G
SH
-P
x
N
o
pa
th
ol
og
y
N
o
Zh
u
et
al
.2
01
6
Cu
N
M
Cu
m
ic
ro
pa
rt
ic
le
~
30
nm
~
25
µm
O
ra
l
Sp
ra
gu
e-
D
aw
le
y
ra
ts
10
0,
20
0
an
d
40
0
m
g/
kg
/d
ay
28
28
da
y
N
M
-in
du
ce
d
in
cr
ea
se
d
AS
T,
AL
T
an
d
to
ta
l
bi
lir
ub
in
ac
tiv
ity
bu
t
no
t
m
ic
ro
pa
rt
ic
le
s
N
ot
an
al
yz
ed
N
o
Le
e
et
al
.2
01
6
(C
on
tin
ue
d
)
JOURNAL OF TOXICOLOGY & ENVIRONMENTAL HEALTH, PART B 145
Ta
bl
e
1.
(C
on
tin
ue
d)
.
N
M
Si
ze
Ro
ut
e
of
N
M
ex
po
su
re
Sp
ec
ie
s
D
os
e
N
um
be
r
of
ex
po
su
re
s
Ex
po
su
re
du
ra
tio
n
H
ep
at
ic
ef
fe
ct
s
H
is
to
pa
th
ol
og
y
Re
co
ve
ry
pe
rio
d
in
cl
ud
ed
/
H
ep
at
ic
re
co
ve
ry
ob
se
rv
ed
Re
fe
re
nc
e
Ti
n
su
lfi
de
na
no
flo
w
er
s
50
,8
0
an
d
20
0
nm
O
ra
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m
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d
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ra
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ra
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at
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at
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ra
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d
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ra
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ra
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/d
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ra
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/d
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at
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ra
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ra
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ra
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/d
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ra
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/d
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ra
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ra
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m
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os
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ra
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ra
l
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at
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er
N
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ed
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ra
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ra
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0.
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45
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N
ot
an
al
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ed
N
o
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ed
an
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ed
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~
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IT
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p
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al
1
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e
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t
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le
ve
ls
N
ot
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ed
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o
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et
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n
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6
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e
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at
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0
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ra
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p
to
7
da
ys
Si
gn
ifi
ca
nt
in
cr
ea
se
s
in
se
ru
m
(IL
-1
α.
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5
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at
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e
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ct
s
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o
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ol
og
y
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o
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et
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.2
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6
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2
~
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~
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0
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N
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e
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ly
IC
R
m
ic
e
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m
g/
kg
pe
r
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y
3
7
da
ys
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ec
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ed
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ve
ls
of
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ru
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n
an
d
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P
H
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c
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ra
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9
4
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ra
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p
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m
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at
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N
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~
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nm
IT
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ta
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ts
0.
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0.
24
m
g/
kg
12
6
w
ee
ks
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al
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ec
re
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es
in
ca
ta
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se
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SH
Px
an
d
SO
D
ac
tiv
ity
H
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he
st
N
M
do
se
–
ne
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ph
il
an
d
ly
m
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oc
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e
in
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tr
at
io
n
an
d
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or
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ic
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ot
ty
ne
cr
os
is
N
o
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et
al
.2
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8
Ti
O
2
~
25
nm
IT
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ra
gu
e-
D
aw
le
y
ra
ts
0.
5,
2.
5
an
d
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m
g/
kg
3
3
or
35
da
ys
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cr
ea
se
d
D
N
A
da
m
ag
e
–
no
t
do
se
de
pe
nd
an
t
N
ot
an
al
yz
ed
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s/
N
A
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lie
r
et
al
.2
01
7
Ti
O
2
-v
e
~
50
nm
+
ve
~
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00
nm
IT
C5
7B
L/
6
m
ic
e
18
,5
4
or
16
2
µg
/a
ni
m
al
1
24
hr
In
cr
ea
se
d
D
N
A
da
m
ag
e
an
d
sa
a3
m
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le
ve
ls
N
ot
an
al
yz
ed
N
o
W
al
lin
et
al
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7
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O
2
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nm
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L/
6
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e
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p
to
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µg
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an
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al
1
24
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d
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ve
ls
N
ot
an
al
yz
ed
N
o
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an
ic
et
al
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7
G
ra
ph
ite
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no
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es
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μm
la
te
ra
l,
5
μm
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te
ra
l
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2
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ra
l
an
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ge
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ra
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n
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L/
6
m
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e
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4
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,
1
da
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7
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ea
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e
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e
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m
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p
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pr
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m
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d
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/d
ay
an
d
el
em
en
ta
l
Cd
Cl
2
–
1
m
g/
kg
/d
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ra
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m
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at
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0
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m
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comparison to controls mice with regards to an
organ-specific inflammatory response, changes in
blood biochemistry, acute phase response and
hepatic pathology as evidenced by marked changes
in intrahepatic architecture, granuloma formation
in different zones of the liver, hepatocyte necrosis,
parenchymatous degeneration, vacuolar genera-
tion and destruction of the liver plates. In addition
and most importantly, alcoholic disease markedly
influenced and hampered organ ability for recov-
ery post-NM challenge. In the same study, in vitro
findings demonstrated ethanol pre-treatment of
HepG2 cells resulted in significantly increased
inflammatory response post-Ag NM exposure.
Thus, data indicate the importance of considera-
tion of susceptible individuals in disease liver
models in NM risk strategies (Kermanizadeh
et al. 2017a).
Lee et al. (2018) administered iv to 6-week-old
male Sprague-Dawley rats weighing approximately
250 g either Au NM (approximately 10 nm), a Ag
NM (approximately 10 nm) or a mixture of both
NM types for a period of 4 weeks (10 or 100 μg/
kg/day for the single NM type exposures or 10/10
or 100/100 μg/kg/day for the mixed NM expo-
sures). Data demonstrated that Ag NMs accumu-
lated in a dose-dependent manner in the liver (up
to 7958.2 ± 817.9 ng/g of tissue). The hepatic Au
concentration increased also in a dose-dependent
manner (up to 3563 ± 1310.7 ng/g of tissue). The
mixed Au/Ag NM exposure in the organ also
enhanced accumulation dose-dependently after
4-week administration, but at a much lower con-
centrations. Importantly, the Au NM showed bio-
persistence and accumulation in liver over
a 4-week period following the single exposure.
This bioaccumulation was significantly less
(almost absent) for the Ag NMs (Lee et al. 2018).
This absence of accumulation of hepatic Ag NMs
might be partially attributed to the dissolution of
materials over a period of 4 weeks.
Further, the bio-distribution of a Zn-labeled
CdSe/CdS/ZnS-QDs (50–100 pmol per animal)
(11 nm) was investigated in FVB/N mice (gender
not disclosed). The animals were exposed to
a single dose of the materials for 2 hr and organ
distribution determined. Bargheer et al. (2015)
noted that liver and spleen were the major organs
to take up the QDs, receiving approximately 70%
of the total injected dose. In addition, iv exposure
resulted in localization of QDs within KCs and the
liver sinusoidal endothelial cells, but not hepato-
cytes (Bargheer et al. 2015).
Yang et al. (2018a) exposed pregnant Sprague-
Dawley rats to a single dose of either 1 or 5 nmol
of a carboxyl coated CdSe/ZnS QD (approximately
20 nm) intravenously. The mother and offspring
were examined for up to 180 days post exposure.
Results showed that QDs primarily accumulated in
livers of the dams at 1 day post exposure.
However, hematology, biochemistry and histology
observations noted limited NM-induced chronic
toxicity in the offspring. In the exposed mothers
at 24 hr, serum ALT, AST, bilirubin and gamma
glutamyl transaminase levels in the high dose
group was significantly increased; however, all
liver biomarkers of damage returned to back-
ground levels by day 10 post injection.
Histopathological analysis also demonstrated
severe hepatic cellular apoptosis, necrosis, cytoly-
sis, blurred hepatic sinus borderline, as well as
a loss of the integrity and morphology of hepatic
lobules in exposed animals at day 1 post exposure.
Once again, all of these changes had largely
resolved by day 18 post exposure (Yang et al.
2018a). Evidence thus indicates the remarkable
ability of liver to regenerate. For assessment of
“real” hepatic nanotoxicology, this study also
demonstrates that a focus on acute responses
alone may be misleading, and that inclusion of
a recovery period might be significantly informa-
tive for both hazard and risk assessment.
In another recent investigation, the toxicity of
a SiO2 NMs (approximately 150 nm) was exam-
ined both in vitro and in vivo. Firstly, male
Sprague-Dawley rats were treated iv with 50 mg/
kg of SiO2 NMs and sacrificed at 48 hr after
a single dose. Further, buffalo rat liver (BRL)
cells were treated with supernatants derived from
SiO2 NM-stimulated KCs (isolated primary cells)
(in vitro 24 hr exposure at a concentration range of
100–800 μg/ml) to determine KC-mediated hepa-
totoxicity. Chen, Xue, and Sun (2013) showed as
compared with control NMs-induced inflamma-
tory cell infiltration at the portal regions of the
liver. In addition, exposure of rats to SiO2 NMs for
48 hr resulted in a significant rise in the number of
KCs in the tissue. Finally, NM exposure produced
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an elevation in AST, total bile acid, cholesterol and
low-density lipoprotein serum levels in these ani-
mals. In vitro data observations indicated that
NMs induced a concentration-dependent release
of hydrogen peroxide (H2O2). Further, KCs stimu-
lated with NMs secreted significant quantities of
the pro-inflammatory cytokine TNF-α. Chen, Xue,
and Sun (2013) also showed that supernatants of
the KCs stimulated with SiO2 NMs, subsequently
reduced cellular viability in BRL cells.
The toxicity and bio-distribution of a 50 nm
SiO2 NM was also investigated following a single
IV exposure at dose of 20 mg/kg for periods of up
to 7 days by Baati et al. (2016). These experiments
were carried out by utilization of 4-week-old athy-
mic nude female mice. This is a questionable
model for a toxicological study as the animals
lack a T lymphocyte population. Baati et al.
(2016) detected a threefold increase of Si content
in livers of exposed animals 24 hr post-NM
administration (106.4 μg/g). However, the NM
liver burden was rapidly degraded and completely
cleared within 7 days. Examination of biochemical
parameters demonstrated a rise in ALT and cata-
lase activity 3 hr post exposure, which returned to
background levels by 24 hr after iv injection.
Finally, no NM-induced hepatic histopathological
damage was found (Baati et al. 2016).
Zhang et al. (2018) investigated both in vitro and
in vivo hepatotoxicity of a mesoporous SiO2 NMs
(approximately 110 nm). In these experiments, L02
cells (hepatocyte cell line) and 6- to 8-week-old
BALB/c mice (wild type, NLRP3−/− and caspase 1−/
−) were utilized. In the in vitro experiments, hepatic
cells were treated with NMs at a concentration range
up to 120 µg/ml for either 24 or 48 hr. For mice,
treatment was via iv route with NMs at doses up to
50 mg/kg, on three occasions every other day, over
a period of 7 days. Firstly, in vitro cytotoxicity data
showed a concentration and time-dependent
decrease in cell viability. The iv NM exposure
resulted in significantly increased serum ALT and
AST levels at doses of 25 and 50 mg/kg. In addition,
IL-1β, IL18 and caspase 1 activity in liver homoge-
nates were also significantly elevated in treated ani-
mals. However, in NLRP3 and caspase 1 KO mice,
liver inflammation and hepatotoxicity observed in
the wild type animals was abolished. Taken together,
data indicated that SiO2 NMs triggered liver
inflammation and hepatocyte cell death through
NLRP3 inflammasome activation (Zhang et al.
2018).
CD-1 strain male mice (8 weeks) were intrave-
nously exposed iv to polyacrylic acid-coated iron
oxide NM (approximately 10 nm) at doses of 8, 20
or 50 mg/kg for 24 hr (Rodrigues et al. 2017).
Histologic observations noted no marked changes
in cellular structures in both 8 and 20 mg/kg NM-
treated animals but in the highest dosed group, 4 of 6
mice had clusters of early necrotic hepatocytes,
mainly in the periportal regions. Further, NMs
were predominantly visible in KCs macrophages as
individual entities. In addition, quantitative analysis
of distribution showed a clear dose-related response
between dose of NMs and area occupied by KCs
loaded with iron (Rodrigues et al. 2017).
The fate of gold/iron oxide hetero-structured
NMs (with two different coatings – amphiphilic
polymer or PEG) (approximately 100 nm) (dose of
56 μg iron) was examined over a period of 1 year (1,
7, 30, 95, 180 or 360 days). Eight-week-old female
C57/BL6 mice weighing approximately 20 g were
administered a single dose iv of the materials. In
the liver, regardless of time after injection and nature
of material coating, NMs were always found within
intracellular vesicles in KCs. Bio-persistent Au mate-
rials become more frequent over time within the
organ (mostly visible in KCs observed in the form
of longer chains, lattices or clusters). It is of interest
that hepatic bio-accumulation was increased twofold
when polymer coating was used in comparison to
the PEG coating. This might be explained by the
reduced opsonization and elevated circulation time
of PEG-coated NMs (Kolosnjaj-Tabi et al. 2015).
Cai et al. (2016) attempted to evaluate the role
of the protein corona in Au NM (nanorods)
(approximately 220 nm) induced hepatotoxicity
and 6–8 week old CD-1 mice were employed. In
this set of trials, NMs were pre-incubated with
mouse serum or mouse serum albumin for 24 hr
before a single iv injection of 5 mg/kg for periods
of either 1, 3, 7 or 28 days. Results showed that
pre-incubation with mouse serum significantly ele-
vated accumulation of Au NMs in liver at 1 day
post injection (over 80% of the injected NMs were
detected in the liver). In addition, clearance of the
materials was markedly influenced by the protein
corona. It is of interest that the Au NMs were
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found exclusively in the KCs. At 3 days post injec-
tion, NM treatment was also associated with sig-
nificantly higher levels of ϒ-glutamyltransferase,
bilirubin and total bile acid compared to controls.
Cai et al. (2016) also noted organ-specific increase
in glutathione (GSH) and antioxidant enzyme
activity in terms of superoxide dismutase (SOD)
and glutathione peroxidase (GSH-Px), suggesting
NM-induced oxidative hepatic stress. Finally, his-
topathological analysis showed no obvious tissue
abnormalities.
The adverse effects of a Au NM (approximately
15 nm) was assessed in 5- to 6-week-old female
BALB/c mice and 5- to 6-week-old female F344
rats. Rodents were exposed to a single iv adminis-
tration 1000 mg/kg of the NMs for a period of up
to 28 days (Bahamonde et al. 2018). No marked
alterations were detected in behavior, body weight
or serum malondialdehyde (MDA), IL18 and IFN-
ϒ levels in any of the animals. Quantification of
Au content in liver rose between 1 and 7 days
post-iv administration and remained high in both
species for the entirety of the 28 days investigated.
The NMs accumulated predominantly in KCs.
By day 14 post exposure, Bahamonde et al.
(2018) observed the formation of micro-
granulomas (macrophage clusters containing mul-
tinucleated giant cells). It should be noted that the
administered NM dose in this study was very high;
therefore, a note of caution is required
i interpretation of the findings. Finally, 3 of the
19 rats exposed to the NMs died unexpectedly
within 24 hr of exposure (Bahamonde et al. 2018).
The organ distribution and toxicity of Au nano-
prisms (thin – 10 nm with flat single crystals, with
three congruent edge lengths of approxi-
mately 150 nm) was investigated following IV
exposure in 6-week-old male and female Swiss
mice (Pérez-Hernández et al. 2017). The animals
were exposed to a single dose of the NMs (6 μg/per
g weight) for 72 hr or 4 months. No significant
alterations in blood biochemistry at either time-
point were found; however,; histological analysis
4 months post exposure showed hepatocytes with
enlarged vacuoles and an abundance of KCs with
black pigments, which were assumed to be the
NMs. Further, Pérez-Hernández et al. (2017)
determined the distribution of the NMs and
reported 25% of injected dose was present in
liver at 72 hr. At 4 months after exposure, tNMs
were still present in liver albeit at reduced quan-
tities (10–15% of the initial injected dose).
In another IV exposure study, Wen et al. (2015)
examined the long term in vivo bio-distribution of
a nano graphene oxide functionalized with poly
sodium 4-styrenesulfonate (approximately
700 nm). In these experiments, male BALB/c
mice (approximately 25 g) were exposed to NMs
at a single dose of 4, 8 or 16 mg/kg of the materials
for up to 180 days (1, 7, 14, 28, 90 and 180 days).
Wen et al. (2015) detected significant increase in
ALT and AST levels on day 1 in the 16 mg/kg
group. With the exception of ALT levels in the
16 mg/kg, all parameters returned to background
levels on day 90. Histopathological analysis of liver
tissues showed characteristic black lesions most
notably in the KCs up to day 180.
In an interesting iv study, male C57BL/6mice, aged
6–8-week-old was exposed to a single dose of lantha-
nide-based up-conversion NM (approximately
40 nm) for 24 hr at doses of up to 150 mg/kg
(Campbell et al. 2018). In these experiments,
a group of animals was pre-treated with clodronate
liposomes to deplete the KC population. First, hema-
toxylin and eosin staining depicted that NM exposure
led to extensive infiltration of inflammatory cells at
the higher doses which was associated with enhanced
serum ALT activity. Surprisingly, pathologic changes
and elevation of ALT levels were increased in clodro-
nate pre-treated mice suggesting that KCs might pro-
tect against lanthanide-based NM-mediated up-
conversion of hepatic injury. In this study, Campbell
et al. (2018) found vast quantities of NMs located in
sinusoids. In the KC depleted livers, NMs were pre-
dominantly observed in hepatocytes, supporting the
hypothesis that KCs act as a filter to prevent the
distribution of NMs to hepatocytes.
Oral route of exposure
Bergin et al. (2016) administered orally to two dif-
ferent Ag NMs (PVP or citrate-stabilized colloidal
suspensions with median hydrodynamic diameters
of 20 and 110 nm, respectively) at doses of 0.1, 1 or
10 mg/kg daily to male C57BL/6 mice (6-weeks-old)
for 3 days. In these experiments, an additional silver
acetate exposure group was included as the ionic Ag
control. The animals were sacrificed on day 3 or 9
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post final Ag NM exposure. Results demonstrated
that between 70% and 98% of the administered Ag
dose was recovered in feces, while particle size and
coating did not significantly influence elimination of
the NMs (peak fecal Ag detected 6–9 hr post-
administration). Bergin et al. (2016) also showed
that 0.5% of total administered dose was detectable
in liver, spleen and intestines at 48 hr post final Ag
NM administration. Finally, no hepatic histopathol-
ogy was observed following the acute Ag NM expo-
sure regime.
Subsequently, the potential adverse effects of Ag
NM (approximately10 nm) on pregnant dams and
embryo-fetal development after maternal exposure
were investigated (Yu et al. 2014). In these set of
experiments, mated female Sprague-Dawley rats
were orally treated daily from gestational days 6–19
with a dose range of up to 1000 mg/kg. The fetuses
were examined for signs of embryotoxic effects after
the final day of exposure. Data demonstrated that at
doses of 100 mg/kg and above there was a significant
decrease in GSH levels and activities of GSH reduc-
tase catalase in maternal liver tissue. However, Yu
et al. (2014) did not find any developmental toxicity
as measured by serum biochemistries, organ weight,
gestation index, fetal deaths, sex ratio or morpholo-
gical alterations of the fetus.
Zinc oxide (ZnO) NMs are considered to exhibit
relative rapid dissolution that contributes to the
toxicity of nano-sized preparations. Oral exposure
of negatively charged ZnO NMs (approximately
30 nm) in 5-week-old male and female Sprague-
Dawley rats daily for 90 days (125, 250 or 500 mg/
kg) followed by a 14-day recovery period resulted in
a dose-dependent accumulation in liver (up to 68.67
ng/g tissue) (Park et al. 2014). Analysis of serum
biochemistry showed a fall in total serum protein
and albumin levels in male mice treated with the
higher doses. However, no marked histopathological
abnormalities were detectable in any of the animals.
Recently, Kong et al. (2018) administered orally
50 nm ZnO 2000–10000 mg/kg for 14 days to male
and female ICR mice (approximately 20 g). Results
demonstrated a LD50 of 5177 mg/kg. The sub-
chronic oral exposure of ZnO NMs produced infil-
tration of inflammatory cells in the portal regions
of the examined livers as well as significantly
higher serum levels of AST and ALT in these
mice. It should be noted that the doses used in
this study are extremely high with little physiolo-
gical relevance (Kong et al. 2018).
In an interesting and comprehensive study, the
influence of co-exposure of two ZnO NMs (either
approximately 14 and 60 nm) and lead (Pb) (as
a means of assessing potential adverse effects of
co-exposure to NMs and heavy metals used in
water treatment facilities) was undertaken in
5-week-old male C57BL/6 mice on normal or
high-fat diets. Jia et al. (2017) orally exposed
mice to NMs (200 mg/kg) or NMs/Pb (200 and
150 mg/kg) daily for a period of 2 weeks. First, it
was noted that both Pb and ZnO materials were
detectable in the liver. The quantification of NMs
or NM/Pb was similar in normal and high-fat
animals. However, co-exposure of ZnO NMs
with Pb elevated the rate of deposition of hepatic
Pb compared to levels of Pb administered alone.
The co-administration increased levels of heavy
metal deposited in the liver by twofold. Jia et al.
(2017) also showed that ZnO NMs or ZnO/Pb
exposure of mice receiving a normal diet resulted
in negligible pathological damage. However, the
same exposures in the high-fat diet mice induced
significant liver injury in addition to the diet-
induced hepatic steatosis. These animals mani-
fested spotty cell necrosis and a mild vacuolar
degeneration. Similarly, a reduction in SOD activ-
ity and a rise in MDA content of liver tissue was
observed only in the high-fat diet mice after expo-
sure to ZnO and Pb. Evidence indicated that the
hepatic toxicity of NMs or co-administration was
significantly augmented by preexisting hepatic dis-
ease initiated by the diet (Jia et al. 2017).
Shrivastava et al. (2014) orally administered to
6-week-old male Swiss albino mice (25–30 g)
a dose of 500 mg/kg of a ZnO (80–100 nm),
TiO2 (50–75 nm) or Al2O3 (40–50 nm) for 21
consecutive days. Significantly increased hepatic
levels of reactive oxygen species (ROS) were
found which were most evident for ZnO NMs.
Further, both SOD and catalase activity declined
in the liver of exposed mice accompanied by a lack
of histopathological alterations in treated animals;
however, in the TiO2-treated group particles were
entrapped within the KCs.
In an interesting investigation, the hepatotoxic
effects of a silica NM (approximately 15 nm) were
examined in normal male Kunming mice or
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a fructose-induced metabolic syndrome model
(approximately 20 g). Li et al. (2018a) fed mice
with either10 mg/kg of the NMs, 30% fructose or
both NMs and fructose daily for a period of
30 days. Histological findings illustrated that in
the metabolic syndrome mouse NMs markedly
exacerbated hepatocyte ballooning which was
accompanied by infiltration of inflammatory
cells. Further, Masson staining demonstrated col-
lagen deposition (an indicator of fibrosis).
Evidence indicates that silica NM exposure
induced increased (and additional) hepatic DNA
damage in the metabolic syndrome mice com-
pared to healthy animals (Li et al. 2018a).
Bai et al. (2018) treated orally male ICR mice
(approximately 30 g) to three differently sized tin
sulfide nanoflower NMs (50, 80 or 200 nm) at doses
of 250–1000 mg/kg for 14 consecutive days. Any size
associated differences were not observed in hepatic
toxicity following exposure to NMs. However, the
oral administration of 50 nm NMs at the highest
doses elevated serum ALT and AST levels. Further,
the expressions of metabolic genes in the liver tissues
were altered following exposure to the 50 nmNMs at
the highest administered dose. In addition, tissues
exposed to 1000 mg/kg of NMs displayed slightly
disrupted cellular arrangements, moderate intersti-
tial hyperemia, sporadic and focal infiltration of
inflammatory cells and moderate apoptosis in the
liver (Bai et al. 2018).
de Carvalho et al. (2018) aimed to investigate the
therapeutic effects of a Au NM (approximately
8 nm) in male Wistar rats (300 g) with alcohol and
methamphetamine-induced liver injury. The ani-
mals were orally treated with three daily doses of
Au NMs (181.48, 362.48 or 724.96 μg/kg) one hr
before administration of ethanol for 28 days. Data
demonstrated that the injured livers exhibited sig-
nificantly greater myeloperoxidase activity than con-
trols which was attenuated in the Au NM (highest
dose) administered animals. Further, Au treatment
elevated hepatic GSH levels. The treatment with
ethanol andmethamphetamine resulted in increased
inflammatory response measured in terms of IL-1β
and TNF-α. The combined treatment of ethanol,
methamphetamine and highest dose of the Au
NMs was associated with enhanced IL10 production
from the liver. Histopathological analysis livers from
diseased animals exhibited fat accumulation,
lymphocyte and neutrophil infiltration, necrosis
and steatosis. However, treatment with Au NMs
produced reduced histopathological damage in the
liver. Finally, evaluation of NF-κB, F4/80, protein
kinase B, phosphatidylinositol-4,5-bisphosphate
3-kinase, procollagen III, allograft inflammatory fac-
tor 1, extracellular signal-regulated kinases 1/2,
transforming growth factor-β, fibroblast growth fac-
tor, SOD 1 and GPx 1 genes suggested that NM
down-regulated activity of KCs and hepatic stellate
cells affecting the profile of their pro-inflammatory
cytokines, oxidative stress and fibrosis (de Carvalho
et al. 2018).
The toxicity of a TiO2 NMs (approximately
75 nm) was investigated in 3- and 8-week-old
male Sprague-Dawley rats following oral exposure
at a dose range up to 200 mg/kg daily for 30 days.
Wang et al. (2013) detected in 3-week-old rats
histopahologic alterations including edema, hepa-
tic cord disarray, perilobular cell swelling, vacuo-
lization and hydropic degeneration at the highest
doses. However, this pathology did not appear in
the adult (8 weeks) rat liver with only mild infil-
tration of mild inflammatory cells observed at the
highest dose. In addition, there were significant
changes in serum biochemistry relating to liver
damage, which again was more apparent in the
younger animals (Wang et al. 2013).
The role of gut-derived axis in TiO2 (30 nm) NM-
induced hepatotoxicity was investigated by Chen
et al. (2019). Four-week-old Sprague-Dawley rats
were administered TiO2 NMs (29 nm) orally at
doses of 2, 10 or 50 mg/kg daily for 90 days.
Significantly increased levels of total protein, albu-
min and globulin were found in 10 or 50 mg/kg
TiO2 NM-exposed animals. In contrast, decreased
levels of total bilirubin, ALT and AST were observed
in the TiO2 exposed animals at 90 days. This is
indicative that AST and ALT activity measurements
might not appropriate for assessment of sub-chronic
liver damage. Histological analysis of the treated rat
tissue demonstrated fatty degeneration of hepato-
cytes, which appeared as fat vacuoles. Further,
a reduction in the level of GSH was accompanied
by an accumulation of hepatic MDA and elevated
GSH-Px and SOD activity in NM-exposed animals.
Finally, the abundance of Lactobacillus-reuteri
increased and abundance of Romboutsia fell signifi-
cantly in feces of TiO2 NM-administered rats. Chen
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et al. (2019) argued that the slight hepatotoxicity
witnessed following NM exposure may be contribu-
ted to alterations in intestinal bacterial species and an
imbalance of oxidation/antioxidation.
Finally, oral administration of a halloysite (Al2
Si2O5(OH)4) nanotube (average length of approxi-
mately 400 nm) was undertaken in a 6–8-week-old
Kunming mouse model. Wang et al. (2018b)
exposed mice to a dose range of 5–300 mg/kg
daily for a period of 30 days. The exposure to the
highest dose of the NMs resulted in hydropic
degeneration with swelling in the cytoplasm of
hepatocytes. In addition to these histopathological
alterations, significantly decreased GSH-Px and
SOD activity in the high dose exposed animals
was noted (Wang et al. 2018b).
Inhalation/intratracheal instillation (IT)/
intranasal route of exposure
The bio-distribution of Znwas determined in 5-week-
old male C57BL/6 mice after exposure to the NMs
(4 hr/day) via a whole-body exposure chamber for
2 weeks (aerosol size distribution 46 ± 1.8 nm; expo-
suremass concentration 3.6 ± 0.5mg/m3) or 13 weeks
(aerosol size distribution 36 ± 1.8 nm; exposure mass
concentration 3.3 ± 0.6 mg/m3). To assess the size
distribution of the ZnO NM aerosol, air from the
chamber was sampled using a scanning mobility par-
ticle sizer spectrometer, while mass concentration of
the aerosol in the whole-body chamber was measured
gravimetrically. In both studies, mice were necropsied
either 1 hr or 3 weeks after the last exposure. Firstly,
Adamcakova-Dodd et al. (2014) noted that 100% of
the ZnO NMs dissolved within the first 24 hr of
mixing in an artificial lysosomal fluid (0.11 M con-
centration of citric acid). A significant rise in levels of
Zn in the liver was found associated with no other
indication of toxicity in secondary organs (including
liver) of the exposed animals. However, a body weight
loss of approximately 2 g was observed after the first
week of exposure in the sub-chronic exposed animals
(Adamcakova-Dodd et al. 2014).
Smulders et al. (2014) examined the bio-
distribution of three “pristine” NMs (TiO2 –
approximately 400 nm; Ag – approximately
90 nm; and SiO2 – approximately 190 nm) and
three aged paints containing NMs in male BALB/
c mice (6-week-old). The animals were exposed to
NMs via oropharyngeal aspiration once a week for
total of 5 weeks (20 µg NMs per exposure) and
sacrificed 2 or 28 days post final administration.
Data showed significant increases in the “pristine”
Ag and SiO2 in the liver of treated animals. It is of
interest that the hepatic metallic content returned
to background levels by 28 days after exposure for
Ag NMs but not for Si (Smulders et al. 2014).
A single IT administration of 4 NiO NMs with
different physiochemical properties at three doses
of up to 6 mg/kg, and for 91 days was carried out
in 12-week-old male F344 rats. Shinohara et al.
(2017) did not observe any NM, dose or time-
dependant alterations in NiO burdens in the livers
of exposed animals (although in some rats the Ni
levels were higher in treated animals compared to
negative group).
The hepatic acute phase response and genotoxic
effect of two differently charged TiO2 NMs (-ve
approximately 50 nm; +ve approximately 1500 nm)
was investigated following a single IT exposure of
6–7 week old female C57BL/6 mice (Wallin et al.
2017). The animals received NMs at doses of 18, 54
or 162 μg/mouse for 24 hr. Data demonstrated NM-
induced hepatic DNA strand breaks for both NMs
but there was no consistent pattern in the differences
between the two NMs. The hepatic acute phase
response was analyzed by measurement of saa3
mRNA levels and found to be increased dose-
dependently 24 hr after exposure for both TiO2
NMs, but only significant at the highest dose utilized.
The systemic toxicity of three sizes of graphite
nanoplates (20 μm lateral, 5 μm lateral, and <2 μm
lateral and 8–25 nm) was undertaken in 8-week-old
male C57BL/6 mice. The animals received 4 or 40 μg
of NMs for 4 hr, 1 day, 7 days, 1 month or 2 months
by pharyngeal aspiration. Results showed that levels
of acute-phase genes (namely – amyloid
P component (Apcs), serum amyloid A1 (Saa1), and
haptoglobin (Hp)) were elevated in the higher dose
groups of the 5 and 20 µm materials. The greatest
responses in liver was noted at 4 hr and 1 day
post exposure and returned to background levels
from day 7 onwards (Roberts et al. 2015).
Finally, Saber et al. (2015) administered to
8-week-old female C57BL/6 mice a single IT dose
of 18, 54 or 162 μg of CNT (diameter – approxi-
mately 15 nm; length 4 μm) or 54, 162 and 486 µg
of sanding dust from an epoxy composite with
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(0.2%) or without CNT for periods of up to
28 days. Pulmonary exposure to CNT, reference
epoxy or CNT epoxy treatment induced
a significant elevation in hepatic Saa1 expression
levels. There were no significant differences in the
response between epoxy dusts or CNT. In addi-
tion, there was no hepatic DNA strand break for
any of the tested materials. The CNT and epoxy
dust with CNTs induced histological changes com-
pared to controls predominantly manifested as
inflammatory cell infiltrations and small and loca-
lized regions of necrosis; however, this pathology
was not observed with the epoxy dust without
CNT (Saber et al. 2015).
Intraperitoneal (ip) injection
In a study using male Wistar albino rats (10–-
12 week old), ZnO NMs (approximately35 nm)
administered a daily intraperitoneal (ip) dose of
2 mg/kg for 21 days significant hepatic histo-
pathology alterations predominantly manifested
as sinusoidal dilatation, KC hyperplasia, inflam-
matory cells infiltration, necrosis, hydropic degen-
eration, hepatocyte apoptosis, anisokaryosis,
nuclear membrane irregularity and glycogen con-
tent depletion (Almansour et al. 2017). However,
the physiological relevance of ip exposure to ZnO
NMs is questionable.
The protective role of a Fe3O4 NM (approximately
35 nm) in Cd2+ -mediated toxicity was investigated
by Zhang et al. (2016). Male Kunming mice (6–-
8 weeks) were administered ip Fe3O4 NM (30 mg/
kg) and CdCl2 (1 mg/kg) once a day for 7 consecu-
tive days. Data showed that in the material only
treated animals, the major % NMs accumulated in
liver and spleen. However, in the co-cadmium and
NM-exposed group the hepatic Fe levels were sig-
nificantly lower. Histopathological analysis of the
livers of NM-treated mice, demonstrated minor
swelling in hepatocytes around the central vein. In
the Cd group, hydropic degeneration was prominent
with spotty necrosis of hepatocytes. In addition,
mesothelial hyperplasia was observed on the liver
surface. However, in co-exposure animals, hepatic
damage was significantly attenuated. Finally, analysis
of serum biochemical parameters revealed that expo-
sure to the NMs alone exerted no marked biological
effect in any of the investigated biomarkers of
hepatic damage. In contrast, mice administered
CdCl2 resulted in significant increases in activities
of ALT, AST, lactate dehydrogenase (LDH) and
levels of total bilirubin (TBIL). Co-exposure attenu-
ated the same hepatic biochemical parameters.
Zhang et al. (2016) concluded co-exposure to Fe3
O4 NMs and CdCl2 significantly attenuates Cd-
induced hepatic damage.
Song et al. (2014) examined the toxicity of ana-
tase TiO2 nanosheets (92.5 nm) for up to 30 days
in 8-week-old C57BL/6 mice following a single ip
injection (10 mg/kg). Bio-distribution data showed
that 4.32% of administered dose was detected in
liver after 24 hr, which was reduced to 4.03%
at day 7 and 1.21% by day 30. However, this
accumulation was not associated with any signifi-
cant histopathological damage at any of the time-
points investigated.
Swiss albino mice (approximately 35 g) were
injected with a single ip dose of a MWCNT (110–-
170 nm and 5–9 mm length) (1.5, 2 or 2.5 mg/kg)
or a mesoporous silica NM (approximately 8 nm)
(doses of 10, 25 or 50 mg/kg) for 7 days.
Determination of AST, ALT, alkaline phosphatase
(ALP) activities and total protein after 7 days
resulted only in a significant increase in AST activ-
ity following exposure to the MWCNTs (Rawat
et al. 2017). This response was not dose depen-
dant. Further, no SiO2 induced hepatic response
was observed in these experiments. It also should
be noted that changes in serum biochemistry at
peak day 7 post exposure might not be ideal for
such measurements.
Dermal route of exposure
The hepatotoxic effects of a dextran-coated ferrite
NM (approximately 85 nm) were investigated in
a guinea pig (300–350 g) model. The NMs were
made into a paste and applied topically on the
clipped upper back region of the animals (80 mg/
animal). This procedure was repeated three times
a week for a period of 3 weeks (a total of 9 doses).
Mohanan et al. (2014) demonstrated no significant
alterations in oxidative stress, changes in hematol-
ogy and biochemical parameters or oxidative
stress-related DNA damage in the livers of
exposed animals.
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In an interesting study, C3.Cg/TifBomTac hairless
mice (10–15 weeks old) were tattooed with either
black or red ink (back of the animal – 1.5 × 4 cm).
These mice were sacrificed after 365 days of being
tattooed and distribution to lymph nodes and per-
ipheral organs was examined. Sepehri et al. (2017)
showed significant ink pigment deposits in the KCs
in 19 of 20 tattooed animals.
Multiple routes of exposure
Ashajyothi, Handral, and Kelmani (2018) examined
hepatotoxicity of Cu and ZnO (16–96 nm) NMs
following ip or iv administration in a 12–13 week
old male Wistar rats. The animals were exposed to
the NMs at a dose range of 6.1 to 19.82 μg/kg (Cu
NMs) and 11.14 to 30.3 μg/kg (ZnO NMs) (single
exposure) for either 14 or 28 days. Data showed that
neither ip nor iv administration of the NMs resulted
in mortality. However, an elevation in serum creati-
nine levels, and activities of ALT, AST and ALP was
noted following treatment with the highest dose
utilized in these experiments. These adverse effects
were greater (albeit mild) for ip compared to iv
route. Ashajyothi, Handral, and Kelmani (2018)
reported toxicity of the ZnO was found to be less
than Cu NMs.
In a bio-distribution study, Fu et al. (2013)
exposed 6–8 week old female ICR mice to meso-
porous silica NMs (110 nm) at a single dose for up
to 7 days (24 hr or 7 days) via either iv, hypoder-
mic, intramuscular (im) and oral routes. Results
demonstrated that small quantities of the NMs
administered im or hypodermic injection localized
in liver but with a low absorption rate. Further,
with oral administration accumulation and persis-
tence in the liver occurred. As expected, iv expo-
sure resulted in the highest accumulation in liver
at 24 hr post-treatment. However, NMs did not
induce any marked changes in hepatic appearance
and micromorphology at 24 hr or 7 days at a dose
of 50 mg/kg (Fu et al. 2013).
In an interesting investigation, Geraets et al.
(2014) determined tissue distribution of 5 differ-
ently sized JRC TiO2 NMs in 9- to 10-week-old
male and female Wistar rats following either oral
or iv treatment (doses of 2.3 mg/rat). The animals
were dosed either once or on 5 consecutive days
and bio-distribution measured at day 2/6, 14, 30
or 90. Following oral exposure, only small quan-
tities of the Ti was detectable in the livers of
treated rats. However, both the single and
repeated IV exposure resulted in rapid distribu-
tion to the liver. Geraets et al. (2014) found that
during the 90 days post exposure period (iv route)
only a decrease of approximately 25% was
observed for the different TiO2 NMs. Overall,
evidence indicated that NM uptake and distribu-
tion combined with slow elimination of NMs
might result in potential long-term tissue
accumulation.
The oral and ip administration of
a polyurethane NM (approximately 250 nm) at
doses of 2, 5 or 10 mg/kg in male Swiss albino
mice (6–8 week old) for a period of 10 days
induced an increase in ALT activity levels (Silva
et al. 2016). Further, histopathological examina-
tion of the liver of the orally treated mice revealed
vascular congestion and vacuolization of hepato-
cytes, as well as inflammatory infiltrate of exposed
animals. Finally, serum IL6 levels were determined
and data demonstrated that 5 or 10 mg/kg of NMs
ip induced a 40–60 fold-enhanced response.
Similarly, following oral administration, IL6 levels
were also increased albeit at lower levels compared
to ip route. Further (Silva et al. 2016) noted
a significant rise in TNF-α levels (approximately
80-fold) in mice administered orally 10 mg/
kg NMs.
Engineered NMs and the liver – in vitro/ex-
vivo studies
Co-culture test model (hepatocytes, KCs and
sinusoidal endothelial cells)
In a unique series of in vitro studies, a 3D primary
human liver spheroid model (compromised of pri-
mary human hepatocytes, KCs and hepatic
endothelial cells) were exposed to a single or long-
term multiple exposure (up to 13 exposures on
every other day) of a panel of NMs (Ag – approxi-
mately 100 nm, ZnO – approximately 200 nm,
MWCNT – D 30 nm, L 700–3000 nm and a posi-
tively charged TiO2 – approximately 250 nm,
CeO2 – approximately 200 nm and DQ12 –
approximately 250 nm) for periods of up to
3 weeks which included recovery periods of up to
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2 weeks for certain exposure scenarios. The results
showed that low dose-repeated exposure to be
more damaging to the liver tissue and more severe
following treatment with Ag and ZnO NMs in
terms of cytotoxicity, cytokine secretion and lipid
peroxidation (Kermanizadeh et al. 2019a, 2019b,
2014c). It was found that KCs are crucial in dictat-
ing the overall hepatic toxicity following exposure
to the materials. Further, findings indicated that
in vitro AST measurement not to be suitable in
a nanotoxicological context. In addition, cytokine
analysis (IL6, IL8, IL10 and TNF-α) proved useful
in demonstrating recovery periods as being suffi-
cient for enabling a reduction in NM-induced pro-
inflammatory responses. Finally, low soluble NM-
treated MT displayed a concentration-dependent
penetration of materials deep into the tissue
(Kermanizadeh et al. 2019a, 2019b, 2014c).
Co-culture test models (hepatocytes and KCs)
In an in vitro study, a comparative analysis of the
toxicological impact of 29 metal oxide NMs
(including cobalt oxide (Co3O4), CuO, Fe3O4,
antimony oxide (Sb2O3), TiO2, tungsten trioxide
(WO3), gadolinium oxide (Gd2O3) and ZnO) was
undertaken by Mirshafiee et al. (2018) in KUP5
(immortalized mice KCs) and Hepa-1-6 cells (mice
hepatocyte cell line). In these experiments, both
cell types were incubated with a panel of NMs for
a period of 24 hr at a concentration range of up to
50 µg/ml. Data demonstrated differences in toxi-
cological profile of metals between hepatocytes
and KUP5. The transition-metal oxides
induced caspases 3 and 7 activation in both cell
types, while rare-earth oxide NMs produced lyso-
somal damage, NLRP3 inflammasome activation,
caspase 1 activation and pyroptosis in KCs but not
hepatocytes. The pyroptosis in KUP5 cells was
accompanied by cell swelling, membrane blebbing,
IL-1β secretion and increased membrane
permeability.
Xue et al. (2014) incubated buffalo rat liver
(hepatocytes) or primary rat KC with a 90 nm
SiO2 NM for a period of 24 hr (up to 1000 µg/
ml). Exposure of hepatocytes to NMs induced
a concentration dependant reduction in cell viabi-
lity and increased mitochondrial damage. Further,
Xue et al. (2014) noted that SiO2 NMs were potent
inducers of TNF-α and nitric oxide in KCs.
Finally, the supernatants from NM-treated KC
were transferred to stimulate BRL cells and found
to inhibit mitochondrial respiratory chain complex
I activity in the hepatocytes.
Co-culture test model (hepatocytes and
sinusoidal endothelial cells)
Tee et al. (2019) utilized a 3D co-culture system
composed of LO2 cells (hepatic cell line) and pri-
mary liver sinusoidal endothelial cells and found
that TiO2 NM (approximately 20 nm) exposure
(500 µM 24 hr) diminished the attachment of the
endothelial cells onto hepatocytes into the hepato-
cyte cell line.
Hepatocyte only test models
Recently Ahmed et al. (2017) incubated HepG2
(human hepatocarcinoma) cells to
a concentration range up to 100 µg/ml of 5 differ-
entially coated Ag NMs bis(2-ethylhexyl)-
sulfosuccinate (AOTAgNM) (approximately
50 nm), cetrimonium bromide (CTABAgNM)
(approximately 75 nm), poly(vinylpyrrolidone)
(PVPAgNM) (approximately 60 nm), poly-
L-lysine (PLLAgNM) (approximately 90 nm) and
bovine serum albumin (BSAAgNM) (approxi-
mately 90 nm) for 24 hr. The findings demon-
strated concentration-dependent effects on
cytotoxicity and genotoxicity in HepG2 cells. The
cytotoxic potential of differentially coated Ag NM
was listed in the order of BSAAgNM > PLLAgNM
> CTABAgNM > AOTAgNM > PVPAgNM. In
addition, treatment of HepG2 cells to non-
cytotoxic concentrations of the Ag NMs-induced
primary DNA damage as evidenced by alkaline
comet assay. Finally, Ahmed et al. (2017) showed
the principal mechanism for NM uptake was
macropinocytosis and clathrin-mediated
endocytosis.
In a 24 hr in vitro exposure of HepG2 cells to
Ag NM (approximately 25 nm), at a concentration
range up to 100 µg/ml, the particles produced
significant cytotoxicity at concentrations above
5 µg/ml (Braeuning et al. 2018). Subsequent ele-
mental analysis of Ag in hepatocytes suggested
that only a small fraction of Ag was taken up (or
JOURNAL OF TOXICOLOGY & ENVIRONMENTAL HEALTH, PART B 159
retained) by the cells (8% of administered concen-
tration). Finally, a comprehensive bioinformatics
analysis of proteomic data at sub-lethal concentra-
tions showed alterations related to redox stress,
mitochondrial dysfunction, intermediary metabo-
lism, inflammatory responses and post-
translational protein modifications (Braeuning
et al. 2018).
Mishra et al. (2016) used HepG2 cells to inves-
tigate the mechanisms underlying toxicity of three
differently sized Ag NMs (10, 50 or 100 nm). In
these experiments, cells were exposed to low con-
centrations of the NMs (≤10 µg/ml). Data demon-
strated that NM exposure was associated with
induction of the autophagy pathway, enhanced
lysosomal activity, increased caspase-3 activity as
well as activation of NLRP3-inflammasome. The
10 nm NMs exhibited the highest cellular
responses compared with larger particles.
Similarly, Sahu et al. (2016) following 24 hr
incubation of HepG2 cells with 20 or 50 nm Ag
NMs at a concentration range up to 50 µg/ml, the
smaller NM-induced micronucleus formation in
the cells, while the exposure to the larger particle
and ionic control produced a significantly weaker
genotoxic response.
Kermanizadeh et al. (2017b) examined the role
of autophagy in HepG2 cell death was investigated
following exposure to a panel of widely used
metallic NMs (Ag – approximately 50 nm;
ZnO – approximately 100 nm; and TiO2 –
approximately 150 nm). The cells were exposed
to the NMs over several periods up to 24 hr. The
time-course investigation of LC3B, atg12, atg3,
atg4b, atg5 and p62 genes and proteins and TEM
analysis showed that the exposure of the ZnO and
Ag NMs resulted in the formation of autophago-
somes followed by a blockage of the development
of the autolysosome. This response was not
observed for the TiO2 NMs. Further, this dysfunc-
tion of the autophagy pathway following exposure
to ZnO and Ag NMs preceded apoptotic cell death
(flow cytometry analysis, cathespin B and caspase
3 activity). A number of alterations in the globu-
lar-actin networks was observed following expo-
sure to the ZnO and Ag NMs (most evident for the
Ag NMs) which appeared more condensed or
bundled compared to controls or TiO2 NM-
exposed cells. Evidence indicates involvement of
the cytoskeleton in the blockage of autophagy in
the ZnO and Ag NM-treated cells (Kermanizadeh
et al. 2017b).
In vitro exposure of HepG2 cells to a collagen-
based ZnO NMs (approximately 50 nm) for 24 hr
showed NMs to be cytotoxic with an inhibitory
concentration 50 (IC50) of 42 µg/ml (Vijayakumar
and Vaseeharan 2018).
Wang et al. (2018a) incubated HepG2 cells with
three different trifluoroethyl aryl ether-based
fluorinated poly (methyl methacrylate) NMs with
5%, 6.1% or 12% fluorine content (all around
600 nm) for a period of 24 hr. All NMs produced
cytotoxicity above100 µg/ml irrespective of fluor-
ine content. The effects of NM exposure on the
cell cycle were also investigated. Data showed that
in NM-treated cells compared with negative con-
trol, the relative % hepatocytes in G0/G1 phase
decreased (4.3–6.8%); while cells in the G2/M
phase rose (3.3–6.7%), suggesting that the mitotic
process was blocked and the cell cycle arrested
(Wang et al. 2018a).
In another in vitro study, Chevallet et al. (2016)
determined the toxic effects of a ZnO NMs
(230 nm) in HepG2 cells with a focus on metal
homeostasis and redox balance disruptions follow-
ing exposure to a concentration up to 30 µg/ml.
A lethal concentration 50% (LC50) of around
20 µg/ml was identified following 24 hr exposure.
Zinc homeostasis disruptions were demonstrated
as evidenced by an up-regulation of metallothio-
nein 1X and zinc transporter 1 and 2 genes.
Further, NM exposure was associated with the
induction of oxidative stress response genes
(heme oxygenase 1 and glutamate-cysteine ligase
were upregulated) (Chevallet et al. 2016).
Thongkam et al. (2017) determined cytotoxicity
and genotoxicity of a panel of 10 engineered NMs
in HepG2 cells. In these experiments, 5 different
TiO2, two ZnO, Ag and two MWCNT (panel of
NMs in the FP7 funded project ENPRA) were
utilized at a concentration of up to 80 µg/cm2 for
24 hr. Data showed Ag and ZnO NM to be highly
cytotoxic. Further, DNA damage, as assessed by
alkaline comet assay, was only detected with Ag
and ZnO, albeit only at cytotoxic concentrations.
In another in vitro toxicological study, the
human liver cell line (HL-7702) and rat liver cell
line (BRL-3A) were exposed to a SiO2 NMs
160 A. KERMANIZADEH ET AL.
(approximately 20 nm) for a period of 72 hr (up to
500 µg/ml). Zuo et al. (2016) noted a concentra-
tion-dependent toxicity with more severe cytotoxi-
city in HL-7702 than BRL-3A cells. The increase in
intracellular and reduced GSH suggested elevated
oxidative stress in both cell types. Western blot
analysis revealed that exposure to the SiO2 NMs
resulted in up-regulation of regulated p53, Bax and
cleaved caspase-3 as well as a down-regulation of
Bcl-2 and caspase-3. Finally, pre-treatment with
the antioxidant ascorbic acid significantly attenu-
ated SiO2 NMs-induced caspase-3 activation.
The in vitro hepatic uptake and toxicity of 40 and
80 nm Au NMs modified with polyethyleneimine
(BPEI), lipoic acid (LA) and polyethylene glycol
(PEG), human plasma protein (HP) and human
serum albumin (HSA) coronas was investigated in
a primary human hepatocyte model following
a 24 hr exposure by Choi, Riviere, and Monteiro-
Riviere (2017). Cells were treated with different
materials up to a concentration of 125 µg/cm2.
From the panel of Au NMs, the BPEI coated NMs
induced the highest toxicity with a LC50 reached.
A time-dependent rise in uptake occurred for all
uncoated NMs with the exception of HP and HSA
coated particles. Further, a time- and concentration-
dependent elevation in ROS/reactive nitrogen spe-
cies (RNS) was correlated with increasing cytotoxi-
city at 24 hr post exposure (Choi, Riviere, and
Monteiro-Riviere 2017).
Exposure of HepG2 cells to Au nanorods
(GNRs) (10 and 25 nm) (10–50 µg/ml) for 48 hr
resulted in a concentration-dependent toxicity
(IC50 for 10 nm GNRs, 25 nm GNRs and quartz
(positive controls NMs) were 20, 27 and 36 µg/ml,
respectively) (Lingabathula and Yellu 2016).
Incubation with GNRs also resulted in
a depletion of intracellular reduced GSH, while
TBARS, caspase 3 and IL8 were all elevated.
In vitro exposure of HepG2 cells for 24 hr to
100 µg/ml of covalently conjugated graphene/Au
(approximately 13 nm) and graphene/Ag
(approximately 50 nm) composites, produced
reduced viability to 65% and 60%, respectively
(Zhou et al. 2014). In addition, inductively coupled
plasma mass spectrometry analysis of intracellular
metal content of HepG2 cells after incubation with
the GO/NMs composites for 24 hr showed metal
content of 40 pg/cell for both NMs.
In a metabolomics study, Kitchin et al. (2014)
treated HepG2 cells to a panel of 4 TiO2 and two
CeO2 NMs at a concentration of 3 or 30 µg/ml for
72 hr. Data demonstrated that five of the NMs
markedly depleted reduced GSH with the greatest
effects induced by exposures to TiO2 (59 nm) and
CeO2 (8 nm). In contrast, a 70 nm anatase TiO2
exerted no significant effect. An addition, CeO2,
but not TiO2, elevated asymmetric dimethylargi-
nine concentrations (involved in cardiovascular
disease, diabetes mellitus and kidney disorders).
Recently Bessa et al. (2017) examined the hepa-
tic toxicity of a free rutile TiO2 NM (approxi-
mately 197 nm in medium), nanocomposites of
the same TiO2 (470 nm in medium) and the
TiO2 NMs anchored in nanokaolin clay (447 nm
in serum-supplemented medium) using HepG2
cells. Cells were exposed to a concentration range
of 5– 300 μg/ml for TiO2 NMs; 45– 2700 μg/ml for
clay and 50 − 3000 μg/ml for TiO2 nanocomposite,
for three exposure periods of 3, 6 or 24 hr.
A significant decrease in cell viability after expo-
sure to all studied NMs was detected, which was
further associated with an increase in HepG2 DNA
damage as assessed by the alkaline comet assay.
Bessa et al. (2017) suggested that the anchoring of
the particular NMs was not associated with
decreased toxicity.
Natarajan et al. (2015) exposed primary rat
hepatocytes to a concentration range (25–100
ppm) of three different commercially available
TiO2 NMs (P25 – 800 nm; anatase – 700 nm and
rutile – 380 nm) for 72 hr. The results showed that
LC50 values of P25, anatase and rutile TiO2 NMs
were 74.13 ± 9.72 ppm, 58.35 ± 4.76 ppm and
106.81 ± 11.24 ppm, respectively. Further, the
three NMs induced a significant loss in hepatocyte
functions (albumin and urea production) and
a potent oxidative response in hepatocytes (effects
most potent for P25).
In an interesting and unique investigation, the
total content of titanium and TiO2 particles was
quantified in 15 human livers postmortem.
Heringa et al. (2018) reported total Ti content in
the liver ranged from 0.02 to 0.09 mg Ti/kg tissue
with an average value of 0.04 ± 0.02 mg. Further,
TiO2 particles were detected in 7 of the 15 livers.
The smallest detected TiO2 particle in the tissue
was 85 nm; with the number-based TiO2 particle
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size distributions in liver calculated as 85–550 nm
(Heringa et al. 2018).
Thai et al. (2016)in a genomic study incubated
HepG2 cells with a panel of 6 differently sized
TiO2 NMs (approximately 20–214 nm) for a period
of 72 hr at concentrations ranging from (0.3–-
30 μg/ml). Exposure to NMs-induced alterations
in differentially expressed genes related to NRF2-
mediated oxidative stress, acute phase response,
cholesterol biosynthesis, fatty acid metabolism,
apoptosis and stellate cell activation.
KC only test model
The mechanism underlying NM-induced activa-
tion of the inflammasome was investigated in
a murine KC line. Kojima et al. (2014) employed
LPS activated KCs which were exposed to three
differently sized Si NMs (approximately 35, 65 and
280 nm) for 24 hr at a concentration range up
to10 µg/cm2. IL-1β production (marker of inflam-
masome activation) was increased in
a concentration-dependent manner in LPS-
primed KCs cells and the greatest response was
to 35 nm Si NMs. This inflammatory response was
partially suppressed by antioxidant (ascorbic acid)
pre-treatment.
In an interesting study, the ability of KCs for
NM uptake was assessed. In this in vitro investiga-
tion, KCs were exposed to three differently sized
PEGylated Au NMs (15, 60 or 100 nm) at a dose of
1 × 1014 nm2/24 plate well for 4 hr. MacParland
et al. (2017) demonstrated that NMs were prefer-
entially taken up by KCs that possessed an M2-like
phenotype (CD163). It was further postulated that
NM uptake selectively impacted the ability of the
resident macrophages to produce pro-
inflammatory cytokines, without altering cellular
viability or phagocytic ability. Further human liver
macrophages were far better than circulating the
blood monocytes at ingestion of Au NMs. Size
effects were not observed.
Discussion
The potential for NMs to translocate to distal
organs following a variety of exposure routes is
a reality, with the liver shown to accumulate
a large proportion of the total or translocated
dose (Antunes et al. 2017; Argueta-Figueroa et al.
2017; Lim et al. 2017). This clearly highlights the
necessity for a thorough investigation of the
impact of NM exposure to normal liver function.
As demonstrated above a large body of toxicology
data has been generated for NMs, using a wide
variety of test systems, experimental protocols and
end-points. It is apparent that all materials are not
equally toxic, and these disparities are to a large
extent based upon their physicochemical proper-
ties and differing experimental designs. Despite
this, from the review of available literature, it is
clear that developments have been made in identi-
fying the potential nanotoxicological effects on the
liver. However, there are still significant knowl-
edge gaps, which require attention to allow for
progression of the field and a better understanding
of potential adverse effects of NMs on the liver.
Summary of in vivo data
A review of the literature clearly indicates that the
route of exposure is extremely important in deter-
mining the proportion of the NM dose that reaches
the liver. Not surprisingly, iv injection of NMs leads
to the largest proportion of administered particle
dose reaching the organ where over 80% of injected
dose was detected at 24 hr post administration (Lee
et al. 2018), since there is no barrier to reaching the
blood, allowing direct transport of the full dose to the
liver sinusoid system. Although, of course, not all of
this initial dose will remain as free NMs on reaching
the liver. It is also evident that NMs translocate to
secondary organs following inhalation and oral
administration (Smulders et al. 2014; Zane et al.
2015). Several investigators suggested that the extent
of uptake of insoluble NMs from the GIT and air-
ways is in the order of approximately 1–5% of the
total applied dose (summarized in Kermanizadeh
et al. 2015), detectable in the liver as early as 24 hr
post exposure (Gosens et al. 2015; Thakur et al.
2014). However, it is worth noting that data indicate
that there are clear differences in biokinetics follow-
ing exposure to NMs by instillation and inhalation
(summarized in Kermanizadeh et al. 2015), which
might be explained by local epithelial membrane
damage following instillation, which seems to result
in increased levels of translocated NMs. Therefore,
caution needs to be exercised when extrapolating
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data from instillation experiments to the (more
representative) inhalation model. A notable number
of instillation studies, however, showed systemic
translocation, bio-distribution and effects on extra-
pulmonary tissues (Gosens et al. 2015; Saber et al.
2015). The vast majority of studies employed metal-
lic elements, metal oxides or organic NMs princi-
pally due to the fact that these can be tracked as
materials (not elemental ions) in tissue (Gosens
et al. 2016; Wallin et al. 2017).
Few studies examined longer-term bio-
distribution of NMs, however, interestingly and
crucially, data demonstrated that low-solubility
materials accumulate in the liver (predominately
in KCs), for relatively long periods of time
(assessed up to 1 year) (Kolosnjaj-Tabi et al.
2015; Sepehri et al. 2017). This suggests that
longer-term consequences of NM exposure need
to be considered in the case of liver, especially for
those that demonstrate bio-persistence.
In terms of investigations that assessed hepatic
hazard of materials, the majority of the NM-induced
effects in liver are observed following exposure to high
doses (inmany instances these are considerably above
physiological relevance) (Kumar and Abraham 2016).
These effects have been measured, but not limited to,
changes in biochemical parameters, antioxidant
depletion, genotoxicity and organ pathology, with
the extent of adversity varying between different
NMs. Inhalation is considered the most important
exposure route from an occupational perspective.
However, only 4 inhalation study were conducted
over the last 5 years in which hepatic effects were
determined (Adamcakova-Dodd et al. 2014; Gosens
et al. 2016; Guo et al. 2020a; Liu et al. 2019), suggest-
ing that this remains a gap in knowledge. Short term
IT studies suggest that NMs have the potential to
induce acute impacts on liver mostly notable in
terms of changes in serum biochemistry associated
with liver damage and DNA damage (Wallin et al.
2017; Yu et al. 2018). However, scrutiny of the data
from the few longer-term inhalation/IT studies, seem
to indicate that generally speaking acute effects resolve
and that this route of exposure only results in rela-
tively non-significant hepatic adverse effects
(Adamcakova-Dodd et al. 2014; Smulders et al. 2014).
Oral administration is also conceived as one of the
principal routes of human NM exposure, in addition
to being the most widely used methodology of
delivering pharmaceuticals. The stability/bio-
availability of NMs in the GIT is extremely uncertain
due to complexities of the physiology of the stomach
and the intestines such as variability of pH in the
biological milieu, the presence of the mucus layer
and numerous digestive enzymes. This issue is
further complicated by the fact that different physio-
chemical characteristics of varying NMs influence
their cellular interactions (Ma et al. 2014). In addi-
tion, the physicochemical characteristics of NMs
may potentially influence how they are affected in
the GIT. From the data published, it was suggested
that the extent of NM dissolution might be the
decisive factor determining uptake into the body
following GIT exposure, and the severity of resulting
systemic (including liver) effects (Kong et al. 2018;
Patlolla, Hackett, and Tchounwou 2015). Overall,
the review of current literature does not enable an
accurate estimation of hepatic adverse effects follow-
ing oral exposure. This being said, from the limited
published data it appears that the distribution of
NMs to the liver following oral exposure is low
(Geraets et al. 2014).
Next, a selected number of in vivo studies reported
that preexisting disease state of the liver is important
not only in augmentation of acute NM-induced
damage (manifested a pathological and biochemical
changes) and but more importantly hampering the
organ’s ability for recovery post-NM challenge (Du
et al. 2018; Kermanizadeh et al. 2017a). This is of
significant importance, as up to 30% of adult popu-
lation globally suffer from a wide spectrum of sub-
clinical often undiagnosed liver damage without any
apparent disease manifestations. Therefore, it is cri-
tical that liver disease is considered for future hazard
and risk assessment strategies for NMs.
From the scrutinization of published data, it is
evidently clear that there are no (with the excep-
tion of Heringa et al. 2018) epidemiological studies
that investigated potential adverse effects of NMs
on human liver. Therefore, despite numerous
in vitro and in vivo publications on the subject
over the last decade the scientific community is
still not that well informed on how NMs actually
affect human liver over a life-time. This is of
crucial importance for enabling more meaningful
hazard assessment strategies but even more essen-
tially as these data would be invaluable to risk
assessors.
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As a final but important note, a NOAEL level was
not included for the studies examine in this review
due to the fact that these doses differ depending
upon specific toxicological end-point being investi-
gated. This further highlights the absolute necessity
to investigate numerous end-points and time-points
to enable more useable realistic data for “real” hazard
and risk assessment purposes.
Highlights of the progress made in in vivo hepa-
tic nanotoxicology 2013–2018
(1) KCs are the main hepatic cell population
relevant for the accumulation of low-
solubility NMs (up to months after initial
dosing) (Bargheer et al. 2015; Kolosnjaj-
Tabi et al. 2015; Rodrigues et al. 2017).
(2) The bio-distribution of NMs to the liver is
not necessarily associated with adverse
effects (Feng et al. 2015; Kolosnjaj-Tabi
et al. 2015; Talamini et al. 2017)
(3) In almost all investigations in which
a recovery period was included the healthy
liver was able to fully recover from NM chal-
lenge (irrespective of NM type, dose or route
of exposure) – this will be discussed in detail
below. To the best of our knowledge, there are
only two studies in which there is no full
hepatic recovery following a recovery period
post-NM exposure (Ni – Magaye et al. 2014;
QD – Tang et al. 2017) (highlighted in Table
1). It should be stated that in these two studies
manifestations of liver damage was mild.
(4) The scrutinization of the literature clearly
revealed that NM-induced adverse effects
in the liver are intensified in the diseased
organ. Further, the disease state of the liver
might influence and hamper the organ’s
ability for recovery post-material challenge
(Du et al. 2018; Kermanizadeh et al. 2017a).
Summary of in vitro data
Numerous studies attempted to assess the nano-
toxicological effects of a wide range of engineered
NMs in in vitro liver models. By examining the
information, these sections aim to establish future
testing strategies to enable more meaningful in
NMs-mediated hepatic toxicity. It is difficult to
draw direct comparisons across in vitro nanotox-
icological studies due to a number of different
variables to consider. For example, NMs of the
same composition are often different between stu-
dies (may vary in physicochemical characteristics
such as size, shape, charge, coating) (Carneiro and
Barbosa 2016). In addition, the experimental pro-
tocols often vary, for example, in the concentra-
tions used, preparation methods of NMs, exposure
times, use of cell lines or primary cells, cell num-
bers, media and the serum protein content
employed. Despite these disparities, one ostensible
pattern is visible across the experimentations –
highly soluble NMs are more toxic than low-
solubility materials both in primary and hepatic
cell lines in vitro. How this relates to in vivo
responses needs to be further investigated, since
in vitro soluble compounds are trapped within the
exposure vessel, while in vivo they diffuse from the
site of dissolution, reducing the localized concen-
tration over time. This issue is discussed further
below.
As an important side note, over the last few years,
a number of in silico approaches were used in an
attempt to ascertain NM-induced hepatotoxicity
in vitro including association with up- and down-
regulation expression analysis of microarrays
(Sooklert et al. 2019), NM-mediated liver genotoxicity
(Guo et al. 2020b) or quantitative structure-activity
relationship (QSAR) modeling (Fourches et al. 2010).
However, in silico analysis falls outside the remits of
this review and will not be discussed further.
Highlights of the progress made in in vitro
hepatic nanotoxicology 2013–2018
(1) Apoptosis and autophagy are important
processes in NM-induced cell death in
hepatocytes in vitro (Kermanizadeh et al.
2017b; Wang et al. 2019)
(2) There have been significance advances in
the development of multi-cellular primary
human hepatic models, which incorporate
important cell populations that are viable
and metabolically active for periods of
weeks allowing for long-term low dose and
164 A. KERMANIZADEH ET AL.
more physiologically relevant exposure of
materials (Kermanizadeh et al. 2019a,
2019b).
Kupffer cells (KC)
KCs are liver resident macrophages that are posi-
tioned within the lumen of the sinusoid.
Importantly, these cells adhere to the sinusoidal
endothelial cells that compose the vessel walls. KCs
are the first immune cells in the liver that come in
contact with the gut bacteria (Nguyen-Lefebvre and
Horuzsko 2015), and any particulate matter trans-
ported to the liver via the portal vein. In a healthy
liver, KCs play a key role in maintenance of liver
immune tolerance (partially due to the exposure to
low levels of gut-originated antigens, KCs are in
a permanent semi-activated state). However, in
pathological conditions, these cells may be activated
and fully differentiate into M1-like or M2-like
macrophages (Beljaars et al. 2014). Due to their
position in the liver sinusoids, these cells are argu-
ably the first andmost important cell population that
encounter non-soluble particulates reaching the
liver. This is one of the reasons, these cells govern
the hepatic immune response to particulate chal-
lenge. In addition, previous in vitro (comparisons
made between 3D primary human liver MT com-
posed of hepatocytes only or co-cultures of hepato-
cytes and KCs) (Kermanizadeh et al. 2019b) and
in vivo (mice with depleted KC cell population)
(Kermanizadeh et al. 2014a) studies clearly demon-
strated that the pro/anti-inflammatory response of
the healthy liver is governed by the resident macro-
phages. Due to their location, the KCs intercept and
capture materials in the sinusoids, consequently pre-
venting a large proportion of the NM dose diffusing
to the hepatocytes. This hypothesis is supported by
observations of the internalization of majority of
NMs in the resident macrophages in vivo (Sepehri
et al. 2017; Wen et al. 2015). However, KCs are not
likely to be 100% effective at preventing hepatocyte
exposure to materials as small NMs might access
hepatocytes via open fenestrations in the liver sinu-
soid endothelial lining.
For this reason, it is highly recommended that
KCs are incorporated in next generation in vitro
hepatic models intended for hazard assessment.
This is even more imperative if the in vitro models
are intended for utilization as a surrogate for in vivo
testing (Kermanizadeh et al. 2019a, 2019b). The use
of in vitro hepatocyte models has been beneficial for
the last three decades in research and various appli-
cation areas. Traditionally, hepatocytes were consid-
ered as the most important cell population in the
liver for drugs and chemical toxicity screening. This
is logical and understandable as drugs and chemical
toxicity is mainly dominated by their metabolism,
with the metabolic intermediates often being hepa-
totoxic. However, since bio-persistent NMs are not
necessarily metabolized, but rather first interact and/
are internalized by KCs (Aalapati et al. 2014;
Shrivastava et al. 2014), the use of hepatocyte only
mono-cultures might not be appropriate for particle
hepatic toxicity screening. It is also important to
consider that numerous investigators demonstrated
that only a small proportion of the administered
dose of any bio-persistent material reaches the hepa-
tocytes in vivo (Sepehri et al. 2017; Wen et al. 2015).
From these data, it is clear that KCs are highly
involved both in NM-induced hepatic biological
responses and in their accumulation.
Meaningful in vitro to in vivo hepatic
comparisons and limitations
Despite the highlighted substantial progress in hepa-
tic in vitro test systems over the last 5 years, studies
still have certain major limitations, which need to be
considered and are discussed below. It is generally
acknowledged that it is not always possible to make
direct or meaningful comparisons between in vitro
and in vivo hepatic toxicological responses. As with
other non-hepatic models systems, one of the key
reasons for the lack of comparability between biolo-
gical responses between in vitro and in vivo systems
is that biological responses may not be similar which
can often be explained by the many limitations of
traditional mono-cellular in vitro test systems
(Kermanizadeh et al. 2016).
These confines include lack of cross-talk
between different cell types (cellular signaling)
and different organs, difficulties in equating dosi-
metry between in vitro and in vivo models, diffi-
culty to reproduce environmentally or
physiologically relevant routes of exposure,
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difficulty to reproduce the exact protein corona,
etc.; and difficulties in identifying endpoints
in vitro that can be measured in vivo or vice
versa. With respect to the last issue, the key is to
identify key biomarkers in vitro that might be
related to in vivo responses. As an example, cyto-
toxicity measurements in vitro are often not suffi-
cient to equate or compare to an in vivo response.
Of particular importance and unique for the liver,
is the necessity for consideration of the inability of
in vitro models to emulate the liver’s unparalleled
regeneration capability. The livers ability to regen-
erate is essential in disease recovery and in distin-
guishing the ability of different NMs to induce
longer-term harm to the human liver. This con-
sideration of liver recovery therefore needs to be
incorporated in future in vitro and in vivo NM
hazard assessment strategies.
In future, assessment of NM-induced cytotoxi-
city to hepatocytes in vitro might be more useful
for the identification of sub-lethal doses for further
study. Even for simple ranking studies, limitations
such as lack of clearance, repeated dose and poten-
tial for recovery need to be considered. As an
alternative to assessment of cytotoxicity, other
meaningful organ-specific relevant toxicological
end-points/biomarkers might be cogitated. Some
recommendations on this are offered in the follow-
ing section. Further, from analysis of the literature
(and our own work), it is suggested that a note of
caution is required to avoid over-emphasis of the
significance of a hepatic biological response. As
two examples of this: a) an increased cytokine
secretion by a hepatocyte cell line in vitro might
not necessarily equate to a hepatic inflammatory
response in vivo; b) an analysis of blood biomar-
kers relating to liver toxicity in isolation (without
other additional toxicological end-points) and at
single time-point does not equate to liver damage
(Yang et al. 2018b).
As described above, the traditional simple
in vitro models that are widely used may provide
some artifacts for NMs that vary in solubility. For
example, a 24 hr in vitro exposure of C3A cells
(derivative of HepG2 cells) or primary hepatocytes
to relatively soluble Ag NMs resulted in significant
cytotoxicity. In comparison, an iv injection of mice
to a relatively high dose of the same Ag NM
resulted in acute increased blood biomarkers of
liver damage and severe histopathological damage.
Yet 1 week post exposure, serum biochemistries
returned to background levels and histopathologi-
cal damage had completely resolved. In addition,
Ag was completely cleared from the organ 1 week
post exposure (Kermanizadeh et al. 2012; 2013;
Kermanizadeh et al. 2017a; Kermanizadeh et al.
Personal communication). For a relatively insolu-
ble TiO2 NM, minimal toxicity was detected in
hepatocytes in vitro, along with no marked impact
on acute measures of serum biochemistries and
histopathology. This was also noted in vivo follow-
ing an in vivo iv exposure of mice. However,
importantly the TiO2 NM bio-persisted and was
still detectable in the liver several weeks post expo-
sure in experimental rodent models
(Kermanizadeh et al. 2012; 2013; Kermanizadeh
et al. Personal communication) as well as impor-
tantly in human liver postmortem (Heringa et al.
2018).
These simplified comparisons, which accentuate
the organ’s regeneration ability and importance of
a material’s bio-persistence, imply that current
in vitro hepatocyte hazard assessment strategies
(including cell death) might not necessarily be
meaningful for the prediction of hepatic damage
in vivo.
Future recommendations
In vitro studies
Based upon the advancements in hepatic nano-
toxicology, it is reasonable to state for the
majority of NMs studied in the liver, any mean-
ingful NM-induced adverse effects in the liver
occurred at acute time points with the potential
to resolve (Kermanizadeh et al. 2017a, 2017b;
Yang et al. 2018a), and effects of more relevance
would only take place after long-term exposure
in man (further discussed below). Therefore, it is
essential to establish more advanced, physiologi-
cally relevant in vitro assessment tools for
improved prediction of the adverse effects attrib-
uted to life-time NM exposure in humans (as
discussed above the considerable progress in the
development of multi-cellular primary organoids
over the last few years has been a great success
with this regard). As touched upon above, the
166 A. KERMANIZADEH ET AL.
suitability of 24 hr single exposure in vitro
monocultures of hepatocytes for hazard assess-
ment are questionable. However, these remain
a necessity to distinguish between studies
attempting to answer specific questions and
hazard assessment investigations. Previously
Kermanizadeh et al. (2014b) stated that “data
suggests that even simple in vitro test models
(in this instance utilising only a single cell
type) can be extremely valuable in predicating
the potential liver response in vivo.” Having
scrutinized the literature over the last 6 years,
as well as our own data and all the arguments
above it is difficult to still agree with this state-
ment. Therefore, a number of recommendations
are offered for progression and improvement of
in vitro hepatic nanotoxicology:
(1) The healthy liver’s ability to regenerate and
recover cannot be currently replicated,
mimicked or reproduced in vitro.
Therefore, future meaningful in vitro toxi-
cological data potentially need to be gener-
ated by utilization of low repeated long-
term dosing regimens (Kermanizadeh et al.
2019a).
(2) In vitro acute cytotoxicity (measured as cell
death or viability) assessment alone are not
that useful for hazard ranking of NMs in the
liver, as this end-point has little in vivo rele-
vance and the findings do not relate to in vivo
observations. Therefore, identification and
investigation of organ-specific sublethal toxi-
cological end-points are more meaningful for
forecasting “real”NM-induced in vivo hazard.
Naturally, cytotoxicity assessments contribute
to such studies in order to identify sub-lethal
concentrations.
(3) A distinction is required for analysis and
hazard assessment strategies for high vs.
low-solubility materials. Importantly, the
persistence of low-solubility materials may
need to be considered by addressing longer-
term effects.
(4) The inclusion of KCs is critical in the genera-
tion of physiologically relevant in vitro hepatic
nanotoxicology data (Kermanizadeh et al.
2019b).
In vivo studies
Whilst considerable improvement has been made
over the last 5 years in terms of more sophisticated
and physiologically relevant in vitro hepatic mod-
els (Bell et al. 2018; Khanal et al. 2019), for now,
the use of in vivo models appears to be the most
appropriate method to gain an accurate and reli-
able representation of potential human NM
hazard. This being said physiologically relevant
in vitro models are becoming crucial for supple-
mentation and refinement of in vivo testing.
Further, the ethical implications of any in vivo
study must be fully considered. Similar to in vitro
investigations the implementation of the following
recommendations might significantly improve the
quality and relevance of in vivo data for hazard
assessment purposes:
(1) As discussed above, all in vivo hepatic
hazard assessment studies need to be
designed and executed with intermittent
repeated dosing and most importantly with
recovery periods (Bahamonde et al. 2018;
Yang et al. 2018a, 2018b). Such a protocol
enables either accumulation or clearance of
NMs, manifestation of adverse effects and
potential for organ recovery to be identified,
leading to a more realistic understanding of
the toxic potential of NMs.
(2) As for other substances, NM-induced effects
should not be overstated. For example,
changes in blood biochemistry or redox sta-
tus at a single time-point are not necessarily
representative of pathophysiological liver
toxicity (Baati et al. 2016; Park et al. 2014).
To this end, the investigation of a wider
range of time-points post-material exposure
would be beneficial to assess either recovery
or disease development. This would also
enable the identification of optimum epochs
for different end-points.
(3) A thorough understanding of liver physiol-
ogy is important in design of a high-quality
hepatic nanotoxicology investigation. This
will allow for identification of relevant end-
points and time-points for an accurate iden-
tification of “real” hepatic damage. As an
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example, serum ALT and AST activity levels
only reflect acute liver injury and are usually
lower in chronic liver injury. Therefore,
analysis of serum biomarkers after weeks
of NM exposure might not be entirely rele-
vant or informative.
(4) The liver is constantly bombarded with for-
eign antigens from the gut; therefore, the
organ tolerance is manifested as a bias
toward immune unresponsiveness (Crispe
2014). This factor needs to be considered
in the analysis of certain organ-specific tox-
icological end-points (e.g. inflammation).
(5) It has been reported that NM-induced
adverse effects in the organ are exaggerated
in the diseased liver (Du et al. 2018;
Kermanizadeh et al. 2017a). Moreover, dis-
ease might affect and hamper the organ’s
recovery and regeneration post xenobiotic
exposure. As discussed above an important
and additional complication is that an esti-
mated 25% of the adult general population
globally suffer from a spectrum of sub-
clinical liver damage. Therefore, it is critical
that a range of liver diseases (mild to severe)
be considered for inclusion in future NM
hazard and risk assessment strategies.
(6) It is imperative that distribution and toxicity
assessments are integrated in future in vivo
experiments (ideally over time). It is not
sufficient to demonstrate accumulation of
NMs without the analysis of possible NM-
induced effects. As discussed above accu-
mulation does not necessarily equate to
adverse effects and vice versa.
(7) As highlighted few studies examined effects
of NMs on the liver following inhalation
exposure (in all reality one of the two most
prominent routes of NM exposure). Despite
the technical, ethical and financial difficulty
associated with experiments of this nature,
these studies are urgently needed for the
progression of hepatic nanotoxicology.
(8) Studies need to consider the incorporation
of multiple appropriate end-points to
enable assessment of “real” hazard (with
analysis of biochemistry, organ-specific
inflammation and histopathology highly
recommended)
In order to carry out a well-informed, evidence-
based risk assessment for the emerging NMs,
a thorough understanding of all aspects of NM risk
is required and an important component to achiev-
ing this is the design of physiologically relevant test
systems and experiments. Further, a critical risk
assessment requires knowledge regarding the level
of exposure to the manufactured NM, route of
exposure, bio-persistence in the organism and
inherent toxicity of the material in question. In
addition, specific to the liver toxicology is the organs
regeneration capability, which needs to be incorpo-
rated and considered for all in vitro and in vivo
hazard assessment experiments.
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